2024

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

J CLIN ONCOL. 2024;42(24):2873-2886.

Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies

J CLIN ONCOL. 2024;42(28):3287-3299.

The impact of MICB mismatches in unrelated haematopoietic stem cell transplantation
Amann E, Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Wagner-Drouet E, Valerius T, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Saal T, Schmid-Möglich A, Neuchel C, Schrezenmeier H, Mytilineos J, Fürst D
HLA. 2024;103(6):e15584.

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT
Angelillo P, Alarcon Tomas A, Campodonico E, Novak U, Gabellier L, Blau I, Kwon M, Ram R, Forcade E, Besley C, Vucinic V, Kröger N, Corral L, Vydra J, Ferrari S, von Tresckow B, Rubio M, Hernani R, Sica S, Stölzel F, Rovira M, Wagner-Drouet E, Pérez-Simón J, Castilla-Llorente C, Ferreri A, Hoogenboom J, Sanchez Ortega I, Malard F, Kuball J, Ruggeri A
BONE MARROW TRANSPL. 2024 [Epub ahead of print].

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS
Arrieta-Bolaños E, van der Burg L, Gedde-Dahl T, Robin M, Salmenniemi U, Kröger N, Yakoub-Agha I, Huynh A, Crawley C, Deconinck E, Bulabois C, Forcade E, Tholouli E, van der Hem J, van Balen P, Hoogenboom J, de Wreede L, Malard F, Ruggeri A, Fleischhauer K
BLOOD. 2024;144(16):1747-1751.

Outcomes of Haploidentical Transplants with PT-CY versus 10/10 MUD Transplants with ATG in Germany
Arslan A, Labuhn S, Sala E, Ringhoffer M, Schetelig J, Schroeder T, Bug G, Franke G, Stelljes M, Dreger P, Zeiser R, Teschner D, Bethge W, Eder M, Edinger M, Amann E, Neuchel C, Schmid-Möglich A, Schmeller S, Beyersmann J, Schrezenmeier H, Mytilineos J, Kröger N, Fuerst D
BLOOD ADV. 2024 [Epub ahead of print].

Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study
Ayuk F, Wagner-Drouet E, Wolff D, von Huenerbein N, von Pein U, Klyuchnikov E, von Harsdorf S, Koenecke C, Sayer H, Kröger N
BONE MARROW TRANSPL. 2024;59(8):1092-1096.

Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, Kröger N, Gagelmann N, Talpaz M, Kantarjian H, Gale R
LANCET HAEMATOL. 2024;11(5):e383-e389.

Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
Bazarbachi A, Labopin M, Moukalled N, Kröger N, Rautenberg C, Schetelig J, Finke J, Blau I, Blaise D, Stelljes M, Eder M, Platzbecker U, Dreger P, Bethge W, Tischer J, Burns D, Sengeloev H, Brissot E, Giebel S, Nagler A, Ciceri F, Mohty M
CLIN CANCER RES. 2024;30(9):1778-1787.

Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life
Braun B, Fischbach F, Richter J, Pfeffer L, Fay H, Reinhardt S, Friese M, Stellmann J, Kröger N, Heesen C, Häußler V
MULT SCLER RELAT DIS. 2024;82:105414.

Celebrating the registration of 9.000 patients treated with CAR T cells in the EBMT registry: Collection of real-world data in the context of hematopoietic cellular therapies
Chabannon C, Ruggeri A, Montoto S, van Biezen A, van der Werf S, Markslag A, Sanchez-Ortega I, Camara R, Ljungman P, Mohty M, Kröger N, Sureda A, McGrath E, Bonini C, Kuball J
BEST PRACT RES CL HA. 2024;37(2):101557.

Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms
Chalandon Y, Eikema D, Moiseev I, Ciceri F, Koster L, Vydra J, Passweg J, Rovira M, Ozcelik T, Gedde-Dahl T, Kröger N, Potter V, Yakoub-Agha I, Rambaldi A, Itälä-Remes M, Tanase A, Onida F, Gurnari C, Scheid C, Drozd-Sokolowska J, Raj K, McLornan D, Robin M
BLOOD ADV. 2024;8(18):4792-4802.

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart J, Hoogenboom J, Urbano-Ispizua A, Peters S, Kuball J, Kröger N, Sureda A, Chabannon C, Haanen J, Pedrazzoli P
ANN ONCOL. 2024;35(4):404-406.

Risk factors for Nocardia infection among allogeneic hematopoietic cell transplant recipients: A case-control study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
De Greef J, Averbuch D, Tondeur L, Duréault A, Zuckerman T, Roussel X, Robin C, Xhaard A, Pagliuca S, Beguin Y, Botella-Garcia C, Khanna N, Le Bourgeois A, Van Praet J, Ho A, Kröger N, Ducastelle Leprêtre S, Roos-Weil D, Aljurf M, Blijlevens N, Blau I, Carlson K, Collin M, Ganser A, Villate A, Lakner J, Martin S, Nagler A, Ram R, Torrent A, Stamouli M, Mikulska M, Gil L, Wendel L, Tridello G, Knelange N, de la Camara R, Lortholary O, Fontanet A, Styczynski J, Maertens J, Coussement J, Lebeaux D
J INFECTION. 2024;88(6):106162.

A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)
Domingos V, Nezvalova-Henriksen K, Dadkhah A, Moreno-Martinez M, Ben Hassine K, Pires V, Kröger N, Bauters T, Hassan M, Duncan N, Kalwak K, Ansari M, Langebrake C, Admiraal R
BONE MARROW TRANSPL. 2024 [Epub ahead of print].

Barriers and facilitators in continuous medical education related to allogeneic stem cell transplantation - a qualitative study of physicians
Eickmann S, Wolff D, Kobbe G, Dreger P, Kröger N, Herrmann-Johns A
ONCOL RES TREAT. 2024;47(4):136-144.

Systematic Evaluation of Donor-KIR/Recipient-HLA Interactions in HLA-matched Hematopoietic Cell Transplantation for AML
Fein J, Shouval R, Krieger E, Spellman S, Wang T, Baldauf H, Fleischhauer K, Kröger N, Horowitz M, Maiers M, Miller J, Mohty M, Nagler A, Weisdorf D, Malmberg K, Toor A, Schetelig J, Romee R, Koreth J
BLOOD ADV. 2024;8(3):581-590.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, Richter J, Pfeffer L, Fehse B, Berger S, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese M, Heesen C, Kröger N
MED-CAMBRIDGE. 2024;5(6):550-558.e2.

Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis
Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini M, Kröger N
TRANSPL CELL THER. 2024;30(6):584.e1-584.e13.

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici A, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf G, Kharboutli S, Müller F, Shune L, Davis J, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah A, Fernández de Larrea C
J CLIN ONCOL. 2024;42(14):1665-1675.

Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis
Gagelmann N, Hobbs G, Campodonico E, Helbig G, Novak P, Schroeder T, Schneider A, Rautenberg C, Reinhardt H, Bosques L, Heuser M, Panagiota V, Thol F, Gurnari C, Maciejewski J, Ciceri F, Rathje K, Robin M, Pagliuca S, Rubio M, Rocha V, Funke V, Hamerschlak N, Salit R, Scott B, Duarte F, Mitrus I, Czerw T, Greco R, Kröger N
AM J HEMATOL. 2024;99(5):844-853.

Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation
Gagelmann N, Schuh C, Flossdorf S, Kunadt D, Stelljes M, Blau I, Brecht A, Bethge W, Schroeder T, Wulf G, Sala E, Bug G, Fleischhauer K, Kröger N
AM J HEMATOL. 2024;99(8):1540-1549.

Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation
Gagelmann N, Schuh C, Zeiser R, Stelljes M, Bethge W, Wulf G, Teschner D, Klein S, Wagner-Drouet E, Jost E, Dreger P, Flossdorf S, Kröger N
TRANSPL CELL THER. 2024;30(10):1011.e1-1011.e13.

The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party
Gjærde L, Ruutu T, Peczynski C, Boreland W, Kröger N, Blaise D, Schroeder T, Peffault de Latour R, Gedde-Dahl T, Kulagin A, Sengeløv H, Yakoub-Agha I, Finke J, Eder M, Basak G, Moiseev I, Schoemans H, Koenecke C, Penack O, Perić Z
BONE MARROW TRANSPL. 2024;59(2):255-263.

Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Guièze R, Eikema D, Koster L, Schetelig J, Sengeloev H, Passweg J, Finke J, Arat M, Broers A, Stölzel F, Byrne J, Castilla-Llorente C, Dreger P, Eder M, Gedde-Dahl T, Kröger N, Ribera Santasusana J, Richardson D, Rambaldi A, Yañez L, Van Gelder M, Drozd-Sokolowska J, Raj K, Yakoub-Agha I, Tournilhac O, McLornan D
BONE MARROW TRANSPL. 2024;59(7):950-956.

CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture
Harfmann M, Schröder T, Głów D, Jung M, Uhde A, Kröger N, Horn S, Riecken K, Fehse B, Ayuk F
CANCERS. 2024;16(2):.

Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N
LEUKEMIA. 2024;38(2):386-388.

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda J, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat U, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit R, Scott B, Tamari R, Tefferi A, Vannucchi A, McLornan D, Barosi G
LANCET HAEMATOL. 2024;11(1):e62-e74.

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective phase II study
Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner E, Schmid C, Reinhardt H, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, Wolschke C
HAEMATOLOGICA. 2024;109(5):1469-1479.

Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia
Larue M, Labopin M, Schroeder T, Huang X, Blau I, Schetelig J, Ganser A, Hamladji R, Bethge W, Kröger N, Socié G, Salmenniemi U, Sengeloev H, Dholaria B, Savani B, Nagler A, Ciceri F, Mohty M
HEMASPHERE. 2024;8(10):e70026.

Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Locke F, Filosto S, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill B, Lee C, Zinzani P, Kröger N, López-Guillermo A, Greinix H, Zhang W, Tiwari G, Budka J, Marincola F, To C, Mattie M, Schupp M, Cheng P, Bot A, Shen R, Bedognetti D, Miao H, Galon J
NAT MED. 2024;30(2):507-518.

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk F, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf T, Hofmann W, Klein S, Jost E, Reiter A, Panse J
LEUKEMIA. 2024;38(4):810-821.

Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Orvain C, Schroeder T, Bories C, Gurnari C, Badbaran A, Boyer-Perrard F, Pagliuca S, Rautenberg C, Tavitian S, Panagiota V, Ianotto J, Thol F, Cayssials E, Heuser M, Rubio M, Cassinat B, Daltro de Oliveira R, Sauter C, Maciejewski J, Reinhardt H, Scott B, Ugo V, Kröger N, Kiladjian J, Robin M
BLOOD ADV. 2024 [Epub ahead of print].

Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Maffini E, Labopin M, Kröger N, Finke J, Stelljes M, Schroeder T, Einsele H, Tischer J, Bornhäuser M, Bethge W, Brecht A, Rösler W, Dreger P, Schäfer-Eckart K, Passweg J, Blau I, Nagler A, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2024;59(7):983-990.

Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients
Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C, Niederwieser C, Rathje K, Gagelmann N, Janson D, Wolschke C, Ayuk F, Kröger N
TRANSPL CELL THER. 2024 [Epub ahead of print].

Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas
Massoud R, Naim H, Klyuchnikov E, Janson D, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2024;112(2):276-285.

Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission
Massoud R, Steiner N, Richter J, Gagelmann N, Niederwieser C, Rathje K, Lastovytska I, Schäfersküpper M, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Klyuchnikov E, Kröger N
EUR J HAEMATOL. 2024 [Epub ahead of print].

Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT
Mohty R, Bazarbachi A, Labopin M, Esteve J, Kröger N, Cornelissen J, Blaise D, Socié G, Maury S, Ganser A, Gedde-Dahl T, von dem Borne P, Bourhis J, Bulabois C, Yakoub-Agha I, Pabst C, Nguyen S, Chevallier P, Huynh A, Bazarbachi A, Nagler A, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2024;59(11):1534-1541.

Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy
Mosna F, Borlenghi E, Litzow M, Byrd J, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan E, Gurrieri C, Yeung C, Deeg H, Capelli D, Candoni A, Gotlib J, Lunghi M, Pullarkat S, Lanza F, Galimberti S, Forghieri F, Venditti A, Festuccia M, Audisio E, Marvalle D, Rigolin G, Roti G, DiBona E, Visani G, Albano F, Eisfeld A, Valent P, Huls G, Borthakur G, Krampera M, Martinelli G, Kröger N, Sperotto A, Gottardi M
HAEMATOLOGICA. 2024 [Epub ahead of print].

Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders
Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, Pendleton M, Register A, Heesen C, Kröger N, Schett G, Mackensen A, Podoll A, Gutman J, Furie R, Bayer R, Distler J, Dietrich S, Krönke G, Bullinger L, Walker K
CYTOTHERAPY. 2024 [Epub ahead of print].

Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
Moukalled N, Labopin M, Versluis J, Socié G, Blaise D, Salmenniemi U, Rambaldi A, Gedde-Dahl T, Tholouli E, Kröger N, Bourhis J, Von Dem Borne P, Daguindau E, Forcade E, Nagler A, Esteve J, Ciceri F, Bazarbachi A, Mohty M
AM J HEMATOL. 2024;99(3):360-369.

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study
Mussetti A, Rius-Sansalvador B, Moreno V, Peczynski C, Polge E, Galimard J, Kröger N, Blaise D, Peffault de Latour R, Kulagin A, Mousavi A, Stelljes M, Hamladji R, Middeke J, Salmenniemi U, Sengeloev H, Forcade E, Platzbecker U, Reményi P, Angelucci E, Chevallier P, Yakoub-Agha I, Craddock C, Ciceri F, Schroeder T, Aljurf M, Ch K, Moiseev I, Penack O, Schoemans H, Mohty M, Glass B, Sureda A, Basak G, Peric Z
BONE MARROW TRANSPL. 2024;59(2):232-238.

Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Nabergoj M, Eikema D, Koster L, Platzbecker U, Sockel K, Finke J, Kröger N, Forcade E, Nagler A, Eder M, Tischer J, Broers A, Kuball J, Wilson K, Hunault-Berger M, Collin M, Russo D, Corral L, Helbig G, Mussetti A, Scheid C, Gurnari C, Raj K, Drozd-Sokolowska J, Yakoub-Agha I, Robin M, McLornan D
BONE MARROW TRANSPL. 2024;59(3):395-402.

Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT
Nagler A, Labopin M, Salmenniemi U, Wu D, Blaise D, Rambaldi A, Reményi P, Forcade E, Socié G, Chevallier P, von dem Borne P, Burns D, Schmid C, Maertens J, Kröger N, Bug G, Aljurf M, Vydra J, Halaburda K, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2024;59(11):1563-1576.

Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Nagler A, Ngoya M, Galimard J, Labopin M, Blau I, Kröger N, Gedde-Dahl T, Schroeder T, Burns D, Salmenniemi U, Rambaldi A, Choi G, Peffault de Latour R, Vydra J, Sengeloev H, Eder M, Mielke S, Forcade E, Kulagin A, Ciceri F, Mohty M
AM J HEMATOL. 2024;99(9):1732-1745.

Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)
Niederwieser C, Iacobelli S, Franke G, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller L, Stelljes M, Morozova E, Passweg J, Onida F, Dreger P, Saccardi R, Ladetto M, Salmenniemi U, Bethge W, Poiré X, Kobbe G, McLornan D, Robin M, Kröger N
BONE MARROW TRANSPL. 2024;59(8):1084-1091.

Hematopoietic cell transplantation (HCT) in MDS patients of older age
Niederwieser C, Kröger N
LEUKEMIA LYMPHOMA. 2024;65(5):570-584.

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study
Niederwieser D, Hasenclever D, Berdel W, Biemond B, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy R, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck L, Vucinic V, Löwenberg B, Cornelissen J
HAEMATOLOGICA. 2024 [Epub ahead of print].

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, Niederwieser C, Kunte A, Heidenreich S, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(4):550-557.

Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Ortí G, Gras L, Koster L, Kulagin A, Byrne J, Apperley J, Halaburda K, Blau I, Clark A, Kröger N, Griskevicius L, Carlson K, Collin M, Bloor A, Raiola A, Blaise D, Aljurf M, López-Corral L, Sakellari I, Beguin Y, Wrobel T, de Rosa L, de Lavallade H, Hayden P, McLornan D, Chalandon Y, Yakoub-Agha I
TRANSPL CELL THER. 2024;30(1):93.e1-93.e12.

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn R, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert M, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z
LEUKEMIA. 2024 [Epub ahead of print].

PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
Penack O, Abouqateb M, Peczynski C, Boreland W, Gülbas Z, Gedde-Dahl T, Castilla-Llorente C, Kröger N, Eder M, Rambaldi A, Bonifazi F, Blau I, Stelljes M, Dreger P, Moiseev I, Schoemans H, Koenecke C, Peric Z
BLOOD CANCER J. 2024;14(1):45.

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, Gedde-Dahl T, Blau I, Schroeder T, Salmenniemi U, Kulagin A, Peffault de Latour R, Mielke S, Zeiser R, Moiseev I, Schoemans H, Koenecke C, Peric Z
LEUKEMIA. 2024;38(5):1156-1163.

How risky is a second allogeneic stem cell transplantation?
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Zeiser R, Ciceri F, Schroeder T, Dreger P, Passweg J, Schetelig J, Stelljes M, Blau I, Franke G, Riesner K, Schoemans H, Moiseev I, Peric Z
LEUKEMIA. 2024;38(8):1799-1807.

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte R, Giebel S, Greinix H, Hazenberg M, Kröger N, Mielke S, Mohty M, Nagler A, Passweg J, Patriarca F, Ruutu T, Schoemans H, Solano C, Vrhovac R, Wolff D, Zeiser R, Sureda A, Peric Z
LANCET HAEMATOL. 2024;11(2):e147-e159.

Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation
Piñana J, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen J, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual M, Yeshurun M, Finke J, Groll A, Shaw P, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R
J INFECT DIS. 2024;229(1):83-94.

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with hyperdiploid complex karyotype
Poiré X, Labopin M, Polge E, Ganser A, Socié G, Gedde-Dahl T, Forcade E, Finke J, Chalandon Y, Bulabois C, Yakoub-Agha I, Aljurf M, Kröger N, Blau I, Nagler A, Esteve J, Mohty M
BONE MARROW TRANSPL. 2024;59(2):264-269.

Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT
Polverelli N, Bonneville E, de Wreede L, Koster L, Kröger N, Schroeder T, Peffault de Latour R, Passweg J, Sockel K, Broers A, Clark A, Dreger P, Blaise D, Yakoub-Agha I, Petersen S, Finke J, Chevallier P, Helbig G, Rabitsch W, Sammassimo S, Arcaini L, Russo D, Drozd-Sokolowska J, Raj K, Robin M, Battipaglia G, Czerw T, Hernández-Boluda J, McLornan D
AM J HEMATOL. 2024;99(5):993-996.

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT
Potter V, Gras L, Koster L, Kroger N, Sockel K, Ganser A, Finke J, Labussiere-Wallet H, Peffault de Latour R, Koc Y, Salmenniemi U, Smidstrup Friis L, Jindra P, Schroeder T, Tischer J, Arat M, Pascual Cascon M, de Wreede L, Hayden P, Raj K, Drozd-Sokolowska J, Scheid C, McLornan D, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2024;59(2):224-231.

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Raj K, Eikema D, Lawless S, Koster L, Kunadt D, Kröger N, Platzbecker U, Stelljes M, Bethge W, Holderried T, Fanin R, Zeiser R, Kuball J, Leblond V, Nicholson E, Passweg J, Potter V, Bay J, Bazarbachi A, Corral L, Gurnari C, Scheid C, Drozd-Sokolowska J, Morris T, Hayden P, Yakoub-Agha I, Robin M, McLornan D
BONE MARROW TRANSPL. 2024 [Epub ahead of print].

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard F, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N
AM J HEMATOL. 2024 [Epub ahead of print].

Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation
Rathje K, Gagelmann N, Salit R, Schroeder T, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Robin M, Oechsler S, Heuser M, Rubio M, Maciejewski J, Reinhardt H, Scott B, Kröger N
BONE MARROW TRANSPL. 2024;59(8):1154-1160.

Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
Robin C, Cordonnier C, Tridello G, Knelange N, Xhaard A, Chantepie S, Tanguy-Schmidt A, Schouten H, Yesherun M, Rocha V, Srour M, Kröger N, Ledoux M, Dalgaard J, Thiebaut A, Giardino S, Calore E, Zuckerman T, Groll A, Raida L, Avcin S, Vicent M, Kaare A, Drozd-Sokolowska J, Turlure P, Bretagne S, Mikulska M, Camara R, Cesaro S, Styczynski J
TRANSPL CELL THER. 2024;30(2):235.e1-235.e10.

Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT
Robin M, Gras L, Koster L, Gagelmann N, van Gorkom G, Ederr M, Itälä-Remes M, Zuckerman T, Beguin Y, Schaap N, Drozd-Sokolowska J, Raj K, Hayden P, de Wreede L, Battipaglia G, Polverelli N, Czerw T, Hernandez Boluda J, Kröger N, Yakoub-Agha I, McLornan D
BRIT J HAEMATOL. 2024;204(2):715-718.

Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT
Rovó A, Gras L, Piepenbroek B, Kröger N, Reinhardt H, Radujkovic A, Blaise D, Kobbe G, Niityvuopio R, Platzbecker U, Sockel K, Hunault-Berger M, Cornelissen J, Forcade E, Bourhis J, Chalandon Y, Kinsella F, Nguyen-Quoc S, Maertens J, Elmaagacli A, Mordini N, Hayden P, Raj K, Drozd-Sokolowska J, de Wreede L, McLornan D, Robin M, Yakoub-Agha I, Onida F
AM J HEMATOL. 2024;99(2):203-215.

Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Salas M, Eikema D, Koster L, Maertens J, Passweg J, Finke J, Broers A, Koc Y, Kröger N, Ozkurt Z, Pascual-Cascon M, Platzbecker U, Van Gorkom G, Schroeder T, López-Lorenzo J, Martino M, Chiusolo P, Kaufmann M, Onida F, Gurnari C, Scheid C, Drozd-Sokolowska J, Raj K, Robin M, McLornan D
BONE MARROW TRANSPL. 2024;59(4):479-488.

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: A study from the ALWP of the EBMT
Sanz J, Labopin M, Blaise D, Raiola A, Busca A, Vydra J, Tischer J, Chevallier P, Bramanti S, Fanin R, Socié G, Forcade E, Kröger N, Koc Y, Itälä-Remes M, Zecca M, Nagler A, Brissot E, Spyridonidis A, Bazarbachi A, Giebel S, Piemontese S, Mohty M, Ciceri F
BLOOD ADV. 2024;8(10):2332-2341.

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
Scheid C, Eikema D, van Gelder M, Salmenniemi U, Maertens J, Passweg J, Blaise D, Byrne J, Kröger N, Sockel K, Chevallier P, Bourhis J, Cornelissen J, Sengeloev H, Finke J, Snowden J, Gedde-Dahl T, Cornillon J, Schanz U, Patel A, Koster L, de Wreede L, Hayden P, Raj K, Drozd-Sokolowska J, Gurnari C, Onida F, McLornan D, Robin M, Yakoub-Agha I
BLOOD. 2024;144(4):445-456.

Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients
Schmälter A, Ngoya M, Galimard J, Bazarbachi A, Finke J, Kröger N, Bornhäuser M, Stelljes M, Stölzel F, Tischer J, Schroeder T, Dreger P, Blau I, Savani B, Giebel S, Esteve J, Nagler A, Schmid C, Ciceri F, Mohty M
BLOOD CANCER J. 2024;14(1):76.

Patient engagement in hematopoietic stem cell transplantation and cell therapy: a survey by the EBMT patient engagement task force & transplantation complications working party
Schoemans H, Burns L, Liptrott S, Murray J, Kenyon M, Barata A, Bolaños N, Scholl I, Hamilton B, Phelan R, Buchbinder D, Penack O, Moiseev I, Boreland W, Peczynski C, De Geest S, Sureda A, Snowden J, Shaw B, Peric Z, Kroeger N
BONE MARROW TRANSPL. 2024;59(9):1286-1294.

Post-transplant cyclophosphamide separates graft-versus host disease and graft versus leukemia effects after HLA-matched stem-cell transplantation for acute myeloid leukemia
Shimoni A, Peczynski C, Labopin M, Kulagin A, Meijer E, Cornelissen J, Choi G, Sanz J, Rovira M, Van Gorkom G, Kröger N, Koc Y, Vydra J, Diez-Martin J, Solano C, Patel A, Chiusolo P, Ciceri F, Nagler A, Mohty M
LEUKEMIA. 2024 [Epub ahead of print].

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kröger N, Ayuk F, Stoelzel F, Middeke J, Eder M, Bethge W, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante M, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau I, Burchert A, Wulf G, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhaeuser M, Schmeller S, Schetelig J
BLOOD. 2024;144(14):1532-1542.

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrián N, Barba P, Kwon M, Lopez-Corral L, Martinez-Lopez J, Ferra C, Di Blasi R, Ghesquieres H, Mutsaers P, Calkoen F, Jak M, van Doesum J, Vermaat J, van der Poel M, Maertens J, Gambella M, Metafuni E, Ciceri F, Saccardi R, Nicholson E, Tholouli E, Matthew C, Potter V, Bloor A, Besley C, Roddie C, Wilson K, Nagler A, Campos A, Petersen S, Folber F, Bader P, Finke J, Kroger N, Knelange N, de La Camara R, Kersten M, Mielke S
LEUKEMIA. 2024;38(9):1985-1991.

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, Wagner-Drouet E, Versluis J, Schroeder T, Blau I, Wulf G, Dreger P, Olesen G, Sengeloev H, Kröger N, Potter V, Forcade E, Passweg J, de Latour R, Maertens J, Wilson K, Bourhis J, Finke J, Brissot E, Bazarbachi A, Giebel S, Savani B, Nagler A, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2024;59(2):217-223.

Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation
Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, Rathje K, Urbanowicz T, Kunte A, Engelmann J, Ihne C, Lastovytska I, Lindhauer C, Marquard F, Reichard M, Ryzhkova A, Sabauri R, Schäfersküpper M, Seyedi N, Kalogeropoulos G, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(9):1265-1274.

Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, Kean L, Lee J, Sánchez-Ortega I, Savani B, Schetelig J, Stadtmauer E, Takahashi Y, Atsuta Y, Koreth J, Kröger N, Ljungman P, Okamoto S, Popat U, Soiffer R, Stefanski H, Kharfan-Dabaja M
BONE MARROW TRANSPL. 2024;59(9):1335.

Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: A report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Sureda A, Carpenter P, Bacigalupo A, Bhatt V, de la Fuente J, Ho A, Kean L, Lee J, Sánchez-Ortega I, Savani B, Schetelig J, Stadtmauer E, Takahashi Y, Atsuta Y, Koreth J, Kröger N, Ljungman P, Okamoto S, Popat U, Soiffer R, Stefanski H, Kharfan-Dabaja M
BONE MARROW TRANSPL. 2024;59(6):832-837.

Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis
Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda J, Bose P, Döhner K, Ellis M, Gangat N, Garcia J, Gisslinger H, Gotlib J, Guglielmelli P, Gupta V, Harrison C, Hexner E, Hobbs G, Kiladjian J, Koschmieder S, Kroger N, Kuykendall A, Loscocco G, Mascarenhas J, Masarova L, Mesa R, Mora B, Odenike O, Oh S, Pardanani A, Patel A, Pemmaraju N, Rambaldi A, Rampal R, Sirhan S, Szuber N, Talpaz M, Vachhani P, Vannucchi A, Barbui T
BLOOD. 2024;144(17):1813-1820.

Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation
Weise G, Massoud R, Krause R, Heidenreich S, Janson D, Klyuchnikov E, Wolschke C, Zeck G, Kröger N, Ayuk F
CANCERS. 2024;16(3):.

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study
Weller J, Lengerke C, Finke J, Schetelig J, Platzbecker U, Einsele H, Schroeder T, Faul C, Stelljes M, Dreger P, Blau I, Wulf G, Tischer J, Scheid C, Elmaagacli A, Neidlinger H, Flossdorf S, Bornhäuser M, Bethge W, Fleischhauer K, Kröger N, De Wreede L, Christopeit M
HAEMATOLOGICA. 2024;109(2):431-443.

Chimeric antigen receptor T-cell therapy and fludarabine precision dosing imperatives
Wicha S, Wansing E, Dadkhah A, Ayuk F, Kröger N, Langebrake C
BLOOD ADV. 2024;8(3):797-798.

2023

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

BONE MARROW TRANSPL. 2023;58(2):229-232.

Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A, Mohty M
BONE MARROW TRANSPL. 2023;58(7):784-790.

Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study
Al Hamed R, Ngoya M, Galimard J, Sengeloev H, Gedde-Dahl T, Kulagin A, Platzbecker U, Yakoub-Agha I, Byrne J, Valerius T, Socie G, Kröger N, Blaise D, Bazarbachi A, Sanz J, Ciceri F, Nagler A, Mohty M
CANCER-AM CANCER SOC. 2023;129(17):2645-2654.

Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: A prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study
Averbuch D, de la Camara R, Tridello G, Knelange N, Bykova T, Ifversen M, Dobsinska V, Ayas M, Hamidieh A, Pichler H, Perez-Martinez A, Cesaro S, Sundin M, Badell I, Bader P, Johansson J, Mirci-Danicar O, Sedlacek P, Paillard C, Gibson B, Lawson S, Kroeger N, Corbacioglu S, Mikulska M, Piñana J, Styczynski J, Ljungman P
BONE MARROW TRANSPL. 2023;58(5):558-566.

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Ayuk F, Gagelmann N, von Tresckow B, Wulf G, Rejeski K, Stelljes M, Penack O, Baldus C, Kröger N, Bethge W, Dreger P
BLOOD ADV. 2023;7(18):5316-5319.

Data-driven grading of acute graft-versus-host disease
Bayraktar E, Graf T, Ayuk F, Beutel G, Penack O, Luft T, Brueder N, Castellani G, Reinhardt H, Kröger N, Beelen D, Turki A
NAT COMMUN. 2023;14(1):7799.

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party
Bazarbachi A, Labopin M, Gedde-Dahl T, Remenyi P, Forcade E, Kröger N, Socié G, Craddock C, Bourhis J, Versluis J, Yakoub-Agha I, Salmenniemi U, El-Cheikh J, Bug G, Esteve J, Nagler A, Ciceri F, Mohty M
CLIN CANCER RES. 2023;29(21):4441-4448.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy
Berger S, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk F
HAEMATOLOGICA. 2023;108(2):444-456.

A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation
Bittrich M, Kriegsmann K, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk H, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz C, Tischler H, Görner M, Brand F, Ehmer M, Kröger N
TRANSFUS MED HEMOTH. 2023;50(6):475-490.

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H, Arseniev L, Beier R, Beutel G, Cario G, Fröhlich B, Greil J, Hansmann L, Hasenkamp J, Höfs M, Hundsdoerfer P, Jost E, Kafa K, Kriege O, Kröger N, Mathas S, Meisel R, Nathrath M, Putkonen M, Ravens S, Reinhardt H, Sala E, Sauer M, Schmitt C, Schroers R, Steckel N, Trappe R, Verbeek M, Wolff D, Blasczyk R, Eiz-Vesper B, Maecker-Kolhoff B
J CLIN INVEST. 2023;133(12):.

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384)
Boquoi A, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kröger N, Mai E, Strapatsas J, Haas R, Kobbe G
CANCERS. 2023;15(21):.

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
Bug G, Labopin M, Niittyvuopio R, Stelljes M, Reinhardt H, Hilgendorf I, Kröger N, Kaare A, Bethge W, Schäfer-Eckart K, Verbeek M, Mielke S, Carlson K, Bazarbachi A, Spyridonidis A, Savani B, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(6):710-716.

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden J, Robin M, Lenhoff S, Mielke S, Passweg J, Broers A, Kröger N, Yegin Z, Tan S, Hayden P, McLornan D, Yakoub-Agha I
AM J HEMATOL. 2023;98(1):112-121.

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
Chihara D, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, De Latour R, Byrne J, Krüger W, Bohn J, Platzbecker U, Blau I, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas C, Kreitman R, Hayden P, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I
HAEMATOLOGICA. 2023;108(6):1676-1679.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines
DeFilipp Z, Ciurea S, Cutler C, Robin M, Warlick E, Nakamura R, Brunner A, Dholaria B, Walker A, Kroger N, Bejanyan N, Atallah E, Tamari R, Solh M, Percival M, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern A
TRANSPL CELL THER. 2023;29(2):71-81.

Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
Derigs P, Bethge W, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P
TRANSPL CELL THER. 2023;29(12):750-756.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
Drozd-Sokolowska J, Gras L, Zinger N, Zahrani M, Passweg J, Byrne J, Ho A, Huang X, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, McLornan D, Onida F, Scheid C, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2023;58(2):222-225.

Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation
Essmann S, Heestermans M, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake C
TRANSPL CELL THER. 2023;29(1):42.e1-42.e6.

Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Filippini Velázquez G, Labopin M, Tischer J, Raiola A, Angelucci E, Kulagin A, Galieni P, Bermúdez A, Bulabois C, Kröger N, Díez-Martín J, Kwon M, Nagler A, Schmid C, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2023;58(8):907-915.

Donor Selection for Allogeneic Hematopoietic Cell Transplantation
Fleischhauer K, Tran T, Meisel R, Mytilineos J, Dreger P, Kröger N
DTSCH ARZTEBL INT. 2023;120(15):261-268.

Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany
Frietsch J, Flossdorf S, Beck J, Kröger N, Fleischhauer K, Dreger P, Schetelig J, Bornhäuser M, Hochhaus A, Hilgendorf I
BRIT J HAEMATOL. 2023;201(2):308-318.

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
Gagelmann N, Ayuk F, Klyuchnikov E, Wolschke C, Berger S, Kröger N
HAEMATOLOGICA. 2023;108(10):2799-2802.

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation
Gagelmann N, Badbaran A, Salit R, Gurnari C, Pagliuca S, Panagiota V, Rautenberg C, Cassinat B, Thol F, Wolschke C, Robin M, Heuser M, Rubio M, Maciejewski J, Reinhardt H, Scott B, Kröger N
BLOOD. 2023;141(23):2901-2911.

Reply to Shao and Zhou
Gagelmann N, Kröger N
HAEMATOLOGICA. 2023;108(2):655-656.

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N
HEMASPHERE. 2023;7(7):e921.

Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study
Gagelmann N, Wulf G, Duell J, Glass B, Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk F, Einsele H, Holtick U, Thomson J, Dreger P, Kröger N
BLOOD ADV. 2023;7(4):555-559.

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, Kröger N, Vydra J, Grassi A, Bonifazi F, Czerw T, Anagnostopoulos A, Lioure B, Ruggeri A, Savani B, Spyridonidis A, Sanz J, Peric Z, Nagler A, Ciceri F, Mohty M
CANCER-AM CANCER SOC. 2023;129(23):3735-3745.

Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Giebel S, Labopin M, Schroeder T, Swoboda R, Maertens J, Bourhis J, Grillo G, Salmenniemi U, Hilgendorf I, Kröger N, Poiré X, Cornelissen J, Arat M, Savani B, Spyridonidis A, Nagler A, Mohty M
AM J HEMATOL. 2023;98(4):580-587.

Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT
Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani M, Lioure B, Reményi P, Arat M, Bourhis J, Helbig G, Tbakhi A, Forcade E, Huynh A, Brissot E, Spirydonidis A, Savani B, Peric Z, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(5):506-513.

Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT
Gjærde L, Peczynski C, Polge E, Kröger N, de Latour R, Finke J, Holler E, Blaise D, Helbig G, Salmenniemi U, Potter V, Bunjes D, Erzsebet L, Penack O, Schoemans H, Koenecke C, Basak G, Perić Z
BONE MARROW TRANSPL. 2023;58(11):1279-1281.

KIR2DS4 and Its Variant KIR1D in KIR-AA Genotype Donors Showed Differential Survival Impact in Patients with Lymphoid Disease after HLA-Matched Unrelated Hematopoietic Stem Cell Transplantation
Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Valerius T, Klein S, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Ringhoffer M, Schmeller S, Neuchel C, Rode I, Amann E, Richter A, Schrezenmeier H, Mytilineos J, Fuerst D
TRANSPL CELL THER. 2023;29(7):457.e1-457.e10.

Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M
Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso M, Cerretti R, Wolschke C, Rubio M, Maciejewski J, Kröger N
LEUKEMIA. 2023;37(3):717-719.

Clinical decision‐making and treatment of myelodysplastic syndromes
Hellstrom-Lindberg E, Kröger N
BLOOD. 2023;142(26):2268-2281.

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
Hermans S, Versluis J, Labopin M, Giebel S, van Norden Y, Moiseev I, Blaise D, Díez Martín J, Meijer E, Rovira M, Choi G, Raiola A, Koc Y, Reményi P, Vydra J, Kröger N, Sica S, Martino M, van Gorkom G, Chevallier P, Busca A, Herrera Arroyo C, Brissot E, Peric Z, Nagler A, Shouval R, Ciceri F, Cornelissen J, Mohty M
HEMASPHERE. 2023;7(3):e846.

Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: A study of the Chronic Malignancies Working Party of EBMT
Hernández-Boluda J, Eikema D, Koster L, Kröger N, Robin M, de Witte M, Finke J, Finazzi M, Broers A, Raida L, Schaap N, Chiusolo P, Verbeek M, Hazenberg C, Halaburda K, Kulagin A, Labussière-Wallet H, Gedde-Dahl T, Rabitsch W, Raj K, Drozd-Sokolowska J, Battipaglia G, Polverelli N, Czerw T, Yakoub-Agha I, McLornan D
BONE MARROW TRANSPL. 2023;58(12):1357-1367.

Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT
Kharfan-Dabaja M, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, Bramanti S, Itälä-Remes M, Schmid C, Busca A, Forcade E, Rabitsch W, Zecca M, Kröger N, Bulabois C, Grillo G, Rambaldi A, Fanin R, Zallio F, Di Renzo N, Koc Y, Novis Y, McDonald A, Herrera Arroyo C, Sanz J, Nagler A, Ciceri F, Mohty M
HEMASPHERE. 2023;7(7):e920.

Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Langebrake C, Badbaran A, Dadkhah A, Massoud R, Freiberger P, Ayuk F, Janson D, Wolschke C, Bacher U, Kröger N
EUR J HAEMATOL. 2023;110(2):188-197.

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study
Kriegsmann K, Bittrich M, Sauer S, Tietze-Stolley C, Movassaghi K, Grube M, Vucinic V, Wehler D, Burchert A, Schmidt-Hieber M, Rank A, Dürk H, Metzner B, Kimmich C, Hentrich M, Kunz C, Hartmann F, Khandanpour C, de Wit M, Holtick U, Kiehl M, Stoltefuß A, Kiani A, Naumann R, Scholz C, Tischler H, Görner M, Brand F, Ehmer M, Kröger N
TRANSFUS MED HEMOTH. 2023;50(5):403-416.

Chronological Age Alone Is not Decisive
Kröger N
DTSCH ARZTEBL INT. 2023;120(37):616.

How I treat transplant-eligible patients with myelofibrosis
Kröger N, Wolschke C, Gagelmann N
BLOOD. 2023;142(20):1683-1696.

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling
Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied N, Foà R, Cornelissen J, Lioure B, Benjamin R, Poiré X, Minnema M, Collin M, Lenhoff S, Snowden J, Santarone S, Wilson K, Trigo F, Dreger P, Böhmer L, Putter H, Garderet L, Kröger N, Yaukoub-Agha I, Schönland S, Morris C
HAEMATOLOGICA. 2023;108(4):1105-1114.

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry
Ljungman P, Tridello G, Piñana J, Ciceri F, Sengeloev H, Kulagin A, Mielke S, Yegin Z, Collin M, Einardottir S, Lepretre S, Maertens J, Campos A, Metafuni E, Pichler H, Folber F, Solano C, Nicholson E, Yüksel M, Carlson K, Aguado B, Besley C, Byrne J, Heras I, Dignan F, Kröger N, Robin C, Khan A, Lenhoff S, Grassi A, Dobsinska V, Miranda N, Jimenez M, Yonal-Hindilerden I, Wilson K, Averbuch D, Cesaro S, Xhaard A, Knelange N, Styczynski J, Mikulska M, de la Camara R
FRONT IMMUNOL. 2023;14:1125824.

Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis
Luther M, Henes F, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2023;58(7):755-761.

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Maffini E, Ngoya M, Galimard J, Harbi S, Kröger N, Platzbecker U, Sengeloev H, Craddock C, Potter V, Choi G, Chevallier P, Stölzel F, Tholouli E, Maertens J, Ciceri F, Cornelissen J, Sanz J, Spyridonidis A, Lanza F, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(9):1033-1041.

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
Marquard F, Langebrake C, Janson D, Mahmud M, Dadkhah A, Kröger N, Ayuk F
FRONT ONCOL. 2023;13:1288764.

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT
Nagler A, Labopin M, Kröger N, Schroeder T, Gedde-Dahl T, Eder M, Franke G, Blau I, Salmenniemi U, Socie G, Schetelig J, Stelljes M, Ciceri F, Mohty M
BONE MARROW TRANSPL. 2023;58(12):1339-1347.

Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Ortí G, Gras L, Zinger N, Finazzi M, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, Radujkovic A, Hunault-Berger M, Schroyens W, Zuckerman T, Bourhis J, Chalandon Y, Bloor A, Schots R, de Wreede L, Drozd-Sokolowska J, Raj K, Polverelli N, Czerw T, Hernández-Boluda J, McLornan D, Yakoub-Agha I
AM J HEMATOL. 2023;98(4):628-638.

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota V, Kerschbaum J, Penack O, Stein C, Arends C, Koenecke C, Strzelecka P, Kloos A, Wiegand L, Lasch A, Altwasser R, Halik A, Gabdoulline R, Thomson J, Weibl K, Franke G, Berger C, Hasenkamp J, Ayuk F, Na I, Beutel G, Keller U, Bullinger L, Wulf G, Kröger N, Vucinic V, Heuser M, Damm F
HEMASPHERE. 2023;7(10):e957.

Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
Penack O, Peczynski C, Koenecke C, Polge E, Kuhnl A, Fegueux N, Daskalakis M, Kröger N, Dreger P, Besley C, Schanz U, Bloor A, Ganser A, Forcade E, Corral L, Passweg J, Novak U, Moiseev I, Schoemans H, Basak G, Chabannon C, Sureda A, Averbuch D, Glass B, de la Camara R, Peric Z
J IMMUNOTHER CANCER. 2023;11(4):.

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub-Agha I, Fegueux N, Daskalakis M, Collin M, Dreger P, Kröger N, Schanz U, Bloor A, Ganser A, Besley C, Wulf G, Novak U, Moiseev I, Schoemans H, Basak G, Chabannon C, Sureda A, Glass B, Peric Z
FRONT IMMUNOL. 2023;14:1252811.

Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT
Polverelli N, Hernández-Boluda J, Czerw T, Barbui T, D'Adda M, Deeg H, Ditschkowski M, Harrison C, Kröger N, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi A, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj G, Hayden P, McLornan D, Yakoub-Agha I
LANCET HAEMATOL. 2023;10(1):e59-e70.

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
Robin M, de Wreede L, Schroeder T, Stölzel F, Kröger N, Koster L, Platzbecker U, Finke J, Ganser A, Blaise D, Ciceri F, Maertens J, Labussière Wallet H, Wang J, Chevallier P, Passweg J, Cornelissen J, Nguyen S, Forcade E, Charbonnier A, Bonifazi F, Hayden P, McLornan D, Yakoub-Agha I
HEMASPHERE. 2023;7(4):e851.

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study
Ruutu T, Peczynski C, Houhou M, Polge E, Mohty M, Kröger N, Moiseev I, Penack O, Salooja N, Schoemans H, Duarte R, Schroeder T, Passweg J, Wulf G, Ganser A, Sica S, Arat M, Salmenniemi U, Broers A, Bourhis J, Rambaldi A, Maertens J, Halaburda K, Zuckerman T, Labussière-Wallet H, Basak G, Koenecke C, Perić Z
BONE MARROW TRANSPL. 2023;58(11):1209-1214.

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
Saccardi R, Putter H, Eikema D, Busto M, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk F, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari A, Chabannon C, Corbacioglu S, Dolstra H, Duarte R, Dulery R, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Labopin M, Lee J, Ljungman P, Manson L, Mensil F, Milpied N, Mohty M, Oldani E, Orchard K, Passweg J, Pearce R, de Latour R, Poirel H, Rintala T, Rizzo J, Ruggeri A, Sanchez-Martinez C, Sanchez-Guijo F, Sánchez-Ortega I, Trnková M, Ferreiras D, Wilcox L, de Wreede L, Snowden J
BONE MARROW TRANSPL. 2023;58(6):659-666.

Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
Schoettler M, Carreras E, Cho B, Dandoy C, Ho V, Jodele S, Moissev I, Sanchez-Ortega I, Srivastava A, Atsuta Y, Carpenter P, Koreth J, Kroger N, Ljungman P, Page K, Popat U, Shaw B, Sureda A, Soiffer R, Vasu S
TRANSPL CELL THER. 2023;29(3):151-163.

Evaluation of a short instrument for measuring health-related quality of life in oncological patients in routine care (HELP-6): an observational study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kroger N, Muller V, Krüll A, Schulz H, Bleich C
FRONT PSYCHOL. 2023;14:1158449.

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
Schroeder T, Stelljes M, Christopeit M, Esseling E, Scheid C, Mikesch J, Rautenberg C, Jäger P, Cadeddu R, Drusenheimer N, Holtick U, Klein S, Trenschel R, Haas R, Germing U, Kröger N, Kobbe G
HAEMATOLOGICA. 2023;108(11):3001-3010.

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Schubert M, Bethge W, Ayuk F, von Bonin M, Vucinic V, Wagner-Drouet E, Subklewe M, Baldus C, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp M, Wulf G, Kröger N, Dreger P
BLOOD ADV. 2023;7(20):6191-6195.

Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT
Spyridonidis A, Labopin M, Savani B, Giebel S, Bug G, Schönland S, Kröger N, Stelljes M, Schroeder T, McDonald A, Blau I, Bornhäuser M, Rovira M, Bethge W, Neubauer A, Ganser A, Bourhis J, Edinger M, Lioure B, Wulf G, Schäfer-Eckart K, Arat M, Peric Z, Schmid C, Bazarbachi A, Ciceri F, Nagler A, Mohty M
HEMASPHERE. 2023;7(1):e812.

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post-transplant myelofibrosis relapse
Srivastava B, Wolschke C, Gagelmann N, Badbaran A, Kröger N
CLIN CASE REP. 2023;11(9):e7942.

Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT
Styczynski J, Tridello G, Koster L, Knelange N, Wendel L, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, Baldomero H, Chabannon C, Corbacioglu S, Dolstra H, Glass B, Greco R, Kröger N, de Latour R, Mohty M, Neven B, Peric Z, Snowden J, Sureda A, Yakoub-Agha I, de la Camara R
BONE MARROW TRANSPL. 2023;58(8):881-892.

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT
Swoboda R, Labopin M, Giebel S, Schroeder T, Kröger N, Arat M, Savani B, Spyridonidis A, Hamladji R, Potter V, Berceanu A, Yakoub-Agha I, Rambaldi A, Ozdogu H, Sanz J, Nagler A, Mohty M
BONE MARROW TRANSPL. 2023;58(3):282-287.

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
Tilmont R, Yakoub-Agha I, Eikema D, Zinger N, Haenel M, Schaap N, Arroyo C, Schuermans C, Besemer B, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson K, Bourhis J, Mateos M, Rabin N, Jost E, Kröger N, Moraleda J, Za T, Hayden P, Beksac M, Mclornan D, Schönland S, Manier S
BONE MARROW TRANSPL. 2023;58(11):1182-1188.

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
Tokaz M, Baldomero H, Cowan A, Saber W, Greinix H, Koh M, Kröger N, Mohty M, Galeano S, Okamoto S, Chaudhri N, Karduss A, Ciceri F, Colturato V, Corbacioglu S, Elhaddad A, Force L, Frutos C, León A, Hamad N, Hamerschlak N, He N, Ho A, Huang X, Jacobs B, Kim H, Lida M, Lehmann L, de Latour R, Percival M, Perdomo M, Rasheed W, Schultz K, Seber A, Ko B, Simione A, Srivastava A, Szer J, Wood W, Kodera Y, Nagler A, Snowden J, Weisdorf D, Passweg J, Pasquini M, Sureda A, Atsuta Y, Aljurf M, Niederwieser D
TRANSPL CELL THER. 2023;29(4):279.e1-279.e10.

The European landscape on allogeneic haematopoietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: A perspective from the Chronic Malignancies Working Party of the EBMT
Tournilhac O, van Gelder M, Eikema D, Zinger N, Dreger P, Bornhäuser M, Vucinic V, Scheid C, Cornelissen J, Schroeder T, Jindra P, Sengeloev H, Nguyen Quoc S, Stelljes M, Blau I, Mayer J, Paneesha S, Chevallier P, Forcade E, Kröger N, Blaise D, Gribben J, Nielsen B, Johansson J, Kyriakou C, Beguin Y, Pioltelli P, Sampol A, McLornan D, Schetelig J, Hayden P, Yakoub-Agha I
BONE MARROW TRANSPL. 2023;58(6):621-624.

Abdominal emergency surgery in patients with hematological malignancies: a retrospective single-center analysis
von Kroge P, Duprée A, Mann O, Izbicki J, Wagner J, Ahmadi P, Weidemann S, Adjallé R, Kröger N, Bokemeyer C, Fiedler W, Modemann F, Ghandili S
WORLD J EMERG SURG. 2023;18(1):12.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A, Rapoport A, Sureda A, Jacobson C, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie L, Chaganti S, Dickinson M, Dorritie K, Reagan P, McGuirk J, Song K, Riedell P, Minnema M, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani S, Schupp M, To C, Locke F
NEW ENGL J MED. 2023;389(2):148-157.

2022

Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study
Albert M, Sirait T, Eikema D, Bakunina K, Wehr C, Suarez F, Fox M, Mahlaoui N, Gennery A, Lankester A, Beier R, Bernardo M, Bigley V, Lindemans C, Burns S, Carpenter B, Dybko J, Güngör T, Hauck F, Lum S, Balashov D, Meisel R, Moshous D, Schulz A, Speckmann C, Slatter M, Strahm B, Uckan-Cetinkaya D, Meyts I, Vallée T, Wynn R, Neven B, Morris E, Aiuti A, Maschan A, Aljurf M, Gedde-Dahl T, Gurman G, Bordon V, Kriván G, Locatelli F, Porta F, Valcárcel D, Beguin Y, Faraci M, Kröger N, Kulagin A, Shaw P, Veelken J, Diaz de Heredia C, Fagioli F, Felber M, Gruhn B, Holter W, Rössig C, Sedlacek P, Apperley J, Ayas M, Bodova I, Choi G, Cornelissen J, Sirvent A, Khan A, Kupesiz A, Lenhoff S, Ozdogu H, von der Weid N, Rovira M, Schots R, Vinh D
BLOOD. 2022;140(14):1635-1649.

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia
Al Hamed R, Labopin M, Daguindau E, Niittyvuopio R, Huynh A, Socié G, Srour M, Henri Bourhis J, Kröger N, Tholouli E, Choi G, Poiré X, Martin H, Rubio M, Jindra P, Blaise D, Beelen D, Labussière-Wallet H, Nagler A, Bazarbachi A, Mohty M
CANCER MED-US. 2022;11(4):1068-1080.

Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy
Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja M, Orchard K, Schwartz J, Rasheed W, Koh M, Kröger N, Kodera Y, Fakih R, Worel N, Manson L, Rintala T, Tabakhi A, Savani B, Gergis U, Sureda A, Eldridge P, Yakoub-Agha I, Hamadani M, Weisdorf D, Greinix H, Aljurf M
TRANSPL CELL THER. 2022;28(8):455-462.

Nocardia infections in hematopoietic cell transplant recipients: a multicenter international retrospective study of the Infectious Diseases Working Party (IDWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Averbuch D, De Greef J, Duréault A, Wendel L, Tridello G, Lebeaux D, Mikulska M, Gil L, Knelange N, Zuckerman T, Roussel X, Robin C, Xhaard A, Aljurf M, Beguin Y, Le Bourgeois A, Botella-Garcia C, Khanna N, Van Praet J, Kröger N, Blijlevens N, Ducastelle Leprêtre S, Ho A, Roos-Weil D, Yeshurun M, Lortholary O, Fontanet A, de la Camara R, Coussement J, Maertens J, Styczynski J
CLIN INFECT DIS. 2022;75(1):88-97.

Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
Beelen D, Arnold R, Stelljes M, Alakel N, Brecht A, Bug G, Bunjes D, Faul C, Finke J, Franke G, Holler E, Kobbe G, Kröger N, Rösler W, Scheid C, Schönland S, Stadler M, Tischer J, Wagner-Drouet E, Wendelin K, Brüggemann M, Reiser L, Hoelzer D, Gökbuget N
TRANSPL CELL THER. 2022;28(12):834-842.

Detection of human herpes virus 6 DNA and chromosomal integration after allogeneic hematopoietic stem cell transplantation: a retrospective single center analysis
Berneking L, Both A, Langebrake C, Aepfelbacher M, Lütgehetmann M, Kröger N, Christopeit M
TRANSPL INFECT DIS. 2022;24(3):e13836.

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus C, Vucinic V, Mougiakakos D, Topp M, Fante M, Schroers R, Bayir L, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen D, Lengerke C, Kroeger N, Dreger P
BLOOD. 2022;140(4):349-358.

Population dynamics in colonizing vancomycin-resistant Enterococcus faecium isolated from immunosuppressed patients
Both A, Kruse F, Mirwald N, Franke G, Christner M, Huang J, Hansen J, Kröger N, Berneking L, Lellek H, Aepfelbacher M, Rohde H
J GLOB ANTIMICROB RE. 2022;28:267-273.

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Buske C, Dreyling M, Alvarez-Larrán A, Apperley J, Arcaini L, Besson C, Bullinger L, Corradini P, Giovanni Della Porta M, Dimopoulos M, D'Sa S, Eich H, Foà R, Ghia P, da Silva M, Gribben J, Hajek R, Harrison C, Heuser M, Kiesewetter B, Kiladjian J, Kröger N, Moreau P, Passweg J, Peyvandi F, Rea D, Ribera J, Robak T, San-Miguel J, Santini V, Sanz G, Sonneveld P, von Lilienfeld-Toal M, Wendtner C, Pentheroudakis G, Passamonti F
ESMO OPEN. 2022;7(2):.

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
Czerw T, Iacobelli S, Malpassuti V, Koster L, Kröger N, Robin M, Maertens J, Chevallier P, Watz E, Poiré X, Snowden J, Kuball J, Kinsella F, Blaise D, Reményi P, Mear J, Cammenga J, Rubio M, Maury S, Daguindau E, Finnegan D, Hayden P, Hernández-Boluda J, McLornan D, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(2):261-270.

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
Dadkhah A, Wicha S, Kröger N, Müller A, Pfaffendorf C, Riedner M, Badbaran A, Fehse B, Langebrake C
PHARMACEUTICS. 2022;14(6):.

Iron Chelation with Deferasirox increases Busulfan AUC during Conditioning Chemotherapy prior to Allogeneic Stem Cell Transplantation
Essmann S, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake C
TRANSPL CELL THER. 2022;28(2):115.e1-115.e5.

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT
Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, Koster L, Ganser A, Volin L, Sengeloev H, Michallet M, Tischer J, Jindra P, Cascon M, Koc Y, Arat M, Tomaszewska A, Hayden P, de Witte T, Yakoub-Agha I, Kröger N, Robin M
BONE MARROW TRANSPL. 2022;57(5):768-774.

Bridging Chemotherapy: Follicular Lymphoma, Mantle Cell Lymphoma, and CLL
Gagelmann N, Gribben J, Kröger N
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 123-125.

Improving allogeneic stem cell transplantation in myelofibrosis
Gagelmann N, Kroger N
INT J HEMATOL. 2022;115(5):619-625.

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjallé R, Mora B, Ayuk F, Kröger N
HAEMATOLOGICA. 2022;107(8):1840-1849.

High Molecular and Cytogenetic Risk in Myelofibrosis Does Not Benefit From Higher Intensity Conditioning Before Hematopoietic Cell Transplantation: An International Collaborative Analysis
Gagelmann N, Salit R, Schroeder T, Badbaran A, Rautenberg C, Panagiota V, Wolschke C, Thol F, Cassinat B, Robin M, Heuser M, Reinhardt H, Scott B, Kröger N
HEMASPHERE. 2022;6(10):.

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
Gagelmann N, Wolschke C, Salit R, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, Reinhardt H, Ayuk F, Heuser M, Scott B, Kröger N
BLOOD ADV. 2022;6(4):1222-1231.

Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)
Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, Berceanu A, Rambaldi A, Hilgendorf I, Kröger N, Mielke S, Zuckerman T, Sanz J, Busca A, Ozdogu H, Anagnostopoulos A, Savani B, Giebel S, Bazarbachi A, Spyridonidis A, Nagler A, Mohty M
BONE MARROW TRANSPL. 2022;57(12):1803-1809.

Clinical features of hepatitis E infections in patients with hematologic disorders
Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann F
HAEMATOLOGICA. 2022;107(12):2870-2883.

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
Greinix H, Eikema D, Koster L, Penack O, Yakoub-Agha I, Montoto S, Chabannon C, Styczynski J, Nagler A, Robin M, Robinson S, Chalandon Y, Mikulska M, Schönland S, Peric Z, Ruggeri A, Lanza F, De Wreede L, Mohty M, Basak G, Kröger N
HAEMATOLOGICA. 2022;107(5):1054-1063.

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten M, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden J, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua Á, Chen D, Vrhovac R, Gribben J, Kröger N, Einsele H, Yakoub-Agha I
ANN ONCOL. 2022;33(3):259-275.

Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia
Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Christopeit M, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2022;28(5):267.e1-267.e7.

Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission
Klyuchnikov E, Badbaran A, Massoud R, Fritzsche-Friedland U, Freiberger P, Ayuk F, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2022;28(7):374.e1-374.e9.

Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
Koenecke C, Eikema D, Hazelaar S, Schroeder T, Potter V, Kröger N, Bornhäuser M, Finke J, Platzbecker U, Radujkovic A, Ganser A, Salmenniem U, Blaise D, Kobbe G, Meijer E, Friis L, Maertens J, Caballero D, Cornelissen J, Olivieri A, Gulsum O, Hayden P, Onida F, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(10):1607-1611.

Graft-versus-host disease in allogeneic transplantation: the good and the bad
Kröger N
HAEMATOLOGICA. 2022;107(7):1494-1495.

The Number of Stem Cell Transplantations During the COVID-19 Pandemic
Kröger N, Frank S, Neidlinger H, Fleischhauer K, Dreger P
DTSCH ARZTEBL INT. 2022;119(35-36):601-602.

Educational Needs for Physicians
Kröger N, Gribben J, Sánchez-Ortega I
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 203-206.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke F, Miklos D, Jacobson C, Perales M, Kersten M, Oluwole O, Ghobadi A, Rapoport A, McGuirk J, Pagel J, Muñoz J, Farooq U, van Meerten T, Reagan P, Sureda A, Flinn I, Vandenberghe P, Song K, Dickinson M, Minnema M, Riedell P, Leslie L, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon L, Westin J
NEW ENGL J MED. 2022;386(7):640-654.

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
Loke J, Labopin M, Craddock C, Cornelissen J, Labussière-Wallet H, Wagner-Drouet E, Van Gorkom G, Schaap N, Kröger N, Veelken J, Rovira M, Menard A, Bug G, Bazarbachi A, Giebel S, Brissot E, Nagler A, Esteve J, Mohty M
CANCER-AM CANCER SOC. 2022;128(15):2922-2931.

Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema D, de Wreede L, Blok H, Isaksson C, Einsele H, Poiré X, van Dorp S, Nikolousis E, Johansson J, Kobbe G, Zecca M, Arnold R, Gerbitz A, Finke J, Díez-Martín J, Bonifazi F, McQuaker G, Lenhoff S, Rohrlich P, Theobald M, Ljungman P, Collin M, Albert M, Ehninger G, Carlson K, Halaburda K, Lehmberg K, Schönland S, Yakoub-Agha I, Gennery A, Lankester A, Kröger N
BONE MARROW TRANSPL. 2022;57(5):817-823.

Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
Maffini E, Labopin M, Beelen D, Kroeger N, Arat M, Wilson K, Bay J, Ganser A, Martin H, Passweg J, Kottaridis P, Yakoub-Agha I, Porras R, Wagner E, Esteve J, Lanza F, Nagler A, Mohty M
BONE MARROW TRANSPL. 2022;57(10):1556-1563.

Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis
Mannina D, Badbaran A, Wolschke C, Klyuchnikov E, Christopeit M, Fehse B, Kröger N
BONE MARROW TRANSPL. 2022;57(3):510-512.

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT
Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, Ganser A, Nagler A, Snowden J, Robin M, Passweg J, Van Gorkom G, Wallet H, Hoek J, Blok H, De Witte T, Kroeger N, Hayden P, Chalandon Y, Agha I
BONE MARROW TRANSPL. 2022;57(1):23-30.

Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, Ayuk F, Christopeit M, Kröger N
HAEMATOLOGICA. 2022;107(4):857-867.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, Fritzsche-Friedland U, Zander A, Kröger N
BONE MARROW TRANSPL. 2022;57(10):1548-1555.

HEV infection in stem cell transplant recipients-retrospective study of EBMT Infectious Diseases Working Party
Mikulska M, Penack O, Wendel L, Knelange N, Cornelissen J, Blijlevens N, Passweg J, Kroger N, Bruns A, Koenecke C, Bierings M, Piñana J, Labussiere-Wallet H, Ghesquieres H, Diaz M, Sampol A, Averbuch D, de la Camara R, Styczynski J
BONE MARROW TRANSPL. 2022;57(2):167-175.

The first steps towards a diverse and inclusive EBMT: a position paper.
Montoto S, Snowden J, Chabannon C, Corbacioglu S, de la Camara R, Dolstra H, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Mohty M, Murray J, Mueller A, Neven B, Peffault de Latour R, Peric Z, Sánchez-Ortega I, Sureda A, Verhoeven B, Villar A, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(3):343-346.

Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: A study of the Chronic Malignancies Working Party of the EBMT
Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, Finke J, Passweg J, Cornelissen J, Schub N, Veelken J, Beguin Y, Wilson K, Zuckerman T, Hunault-Berger M, Lioure B, Porras R, Turlure P, Kerre T, Koster L, Hayden P, Onida F, Scheid C, Chalandon Y, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(7):1072-1078.

Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT
Nagler A, Labopin M, Arat M, Reményi P, Koc Y, Blaise D, Angelucci E, Vydra J, Kulagin A, Socié G, Rovira M, Sica S, Aljurf M, Gülbas Z, Kröger N, Brissot E, Peric Z, Giebel S, Ciceri F, Mohty M
CANCER-AM CANCER SOC. 2022;128(22):3959-3968.

Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis
Nagler A, Ngoya M, Galimard J, Labopin M, Bornhäuser M, Stelljes M, Finke J, Ganser A, Einsele H, Kröger N, Brecht A, Bethge W, Edinger M, Kulagin A, Passweg J, Blau I, Elmaagacli A, Schäfer-Eckart K, Platzbecker U, Schroeder T, Bunjes D, Tischer J, Martin S, Spyridonidis A, Giebel S, Savani B, Mohty M
CLIN CANCER RES. 2022;28(19):4258-4266.

Correction: Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
Nagler A, Ngoya M, Galimard J, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(12):.

Trends in outcome of transplantation in patients with secondary acute myeloid leukemia: an analysis from the Acute Leukemia Working Party (ALWP) of the EBMT
Nagler A, Ngoya M, Galimard J, Labopin M, Kröger N, Socié G, Gedde-Dahl T, Potter V, Schroeder T, Platzbecker U, Ganser A, Blaise D, Salmenniemi U, Maertens J, Craddock C, Labussière-Wallet H, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(12):1788-1796.

Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt H, Finke J, Franke G, Ciceri F, Verbeek M, Blau I, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(12):.

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt H, Finke J, Franke G, Ciceri F, Verbeek M, Blau I, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani B, Mohty M
BONE MARROW TRANSPL. 2022;57(7):1116-1123.

Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study
Neuchel C, Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Wagner-Drouet E, Valerius T, Kröger N, Wulf G, Einsele H, Thurner L, Schaefer-Eckart K, Freitag S, Casper J, Dürholt M, Kaufmann M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Amann E, Rode I, Schrezenmeier H, Mytilineos J, Fürst D
HLA. 2022;100(4):349-360.

Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C, Kröger N
HEMATOL-AM SOC HEMAT. 2022;2022(1):114-122.

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
Niederwieser C, Weber B, Reichard M, Gagelmann N, Ajib S, Schlipfenbacher V, Zeng Z, Lang F, Janson D, Wolschke C, Ayuk F, Bug G, Kröger N
BONE MARROW TRANSPL. 2022;57(7):1180-1182.

One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh A, Hashmi S, Ho A, Horowitz M, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee J, Martínez-Rolón J, Pasquini M, Passweg J, Paulson K, Seber A, Snowden J, Srivastava A, Szer J, Weisdorf D, Worel N, Koh M, Aljurf M, Greinix H, Atsuta Y, Saber W
HAEMATOLOGICA. 2022;107(5):1045-1053.

Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis J, Finke J, Passweg J, Salmenniemi U, Schouten H, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I
BONE MARROW TRANSPL. 2022;57(6):896-902.

Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey
Passweg J, Baldomero H, Chabannon C, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, Mohty M, Neven B, Peffault de Latour R, Perić Z, Snowden J, Yakoub-Agha I, Sureda A, Kröger N
BONE MARROW TRANSPL. 2022;57(5):742-752.

Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, de la Camara R, Glass B, Duarte R, Kröger N, Schoemans H, Koenecke C, Peric Z, Basak G
BONE MARROW TRANSPL. 2022;57(2):183-190.

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
Perram J, Ross D, McLornan D, Gowin K, Kröger N, Gupta V, Lewis C, Gagelmann N, Hamad N
AM J HEMATOL. 2022;97(11):1464-1477.

Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance
Piechotta V, Skoetz N, Engelhardt M, Einsele H, Goldschmidt H, Scheid C
DTSCH ARZTEBL INT. 2022;119(14):253-260.

Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Raj K, Eikema D, Sheth V, Koster L, de Wreede L, Blaise D, Di Grazia C, Koc Y, Potter V, Chevallier P, Lopez-Corral L, Wu D, Mielke S, Maertens J, Meijer E, Huynh A, Passweg J, Luft T, Pérez-Simón J, Ciceri F, Piekarska A, Hayri Ozsan G, Kröger N, Robin M, Yakoub-Agha I
BLOOD CANCER J. 2022;12(9):140.

High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group
Schaffrath J, Brummer C, Wolff D, Holtick U, Kröger N, Bornhäuser M, Kraus S, Hilgendorf I, Blau I, Penack O, Wittke C, Steiner N, Nachbaur D, Thurner L, Hindahl H, Zeiser R, Maier C, Bethge W, Müller L
TRANSPL CELL THER. 2022;28(6):337.e1-337.e10.

Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socié G, Delgado J, Deconinck E, Damaj G, Maury S, Beelen D, Quoc S, Shankara P, Brecht A, Mayer J, Hunault-Berger M, Bittenbring J, Thieblemont C, Lepretre S, Baldauf H, de Wreede L, Tournilhac O, Yakoub-Agha I, Kröger N, Dreger P
BONE MARROW TRANSPL. 2022;57(2):330.

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
Schetelig J, Hoek J, Stilgenbauer S, Middeke J, Andersen N, Fox C, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede L, Tournilhac O, Kröger N, Yakoub-Agha I, Dreger P
BONE MARROW TRANSPL. 2022;57(1):144.

Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients
Schubert M, Berger C, Kunz A, Schmitt A, Badbaran A, Neuber B, Zeschke S, Wang L, Riecken K, Hückelhoven-Krauss A, Müller I, Müller-Tidow C, Dreger P, Kröger N, Ayuk F, Schmitt M, Fehse B
INT J ONCOL. 2022;60(5):.

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
Snowden J, Sánchez-Ortega I, Corbacioglu S, Basak G, Chabannon C, de la Camara R, Dolstra H, Duarte R, Glass B, Greco R, Lankester A, Mohty M, Neven B, de Latour R, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N
BONE MARROW TRANSPL. 2022;57(8):1217-1239.

Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT
Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G, Ciceri F, Vydra J, Reményi P, Rovira M, Meijer E, Labussière-Wallet H, Blaise D, van Gorkom G, Kröger N, Koc Y, Giebel S, Bazarbachi A, Savani B, Nagler A, Mohty M
BONE MARROW TRANSPL. 2022;57(12):1774-1780.

Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation
Tsamadou C, Gowdavally S, Platzbecker U, Sala E, Valerius T, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Neuchel C, Rode I, Schrezenmeier H, Mytilineos J, Fuerst D
BONE MARROW TRANSPL. 2022;57(10):1539-1547.

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
Waszczuk-Gajda A, Penack O, Sbianchi G, Koster L, Blaise D, Reményi P, Russell N, Ljungman P, Trneny M, Mayer J, Iacobelli S, Kobbe G, Scheid C, Apperley J, Touzeau C, Lenhoff S, Jantunen E, Anagnostopoulos A, Paris L, Browne P, Thieblemont C, Schaap N, Sierra J, Yakoub-Agha I, Garderet L, Styczynski J, Schoemans H, Moiseev I, Duarte R, Peric Z, Montoto S, van Biezen A, Mikulska M, Aljurf M, Ruutu T, Kröger N, Morris C, Koenecke C, Schoenland S, Basak G
J CLIN MED. 2022;11(12):.

2021

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Ayuk F, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, Zeschke S, Kröger N, Fehse B
BLOOD ADV. 2021;5(11):2523-2527.

Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT
Baron F, Ngoya M, Labopin M, Cornelissen J, Ganser A, Forcade E, Sengeloev H, Socié G, Blaise D, Bornhäuser M, Valerius T, Reinhardt H, Kröger N, Ruggeri A, Nagler A, Mohty M
BONE MARROW TRANSPL. 2021;56(11):2742-2748.

Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT
Battipaglia G, Mauff K, Wendel L, Angelucci E, Mohty M, Arcese W, Santarone S, Rubio M, Kroger N, Fox M, Blaise D, Iori A, Fanin R, Chalandon Y, Pioltelli P, Marotta G, Chiusolo P, Sever M, Solano C, Contentin N, de Wreede L, Czerw T, Hernandez-Boluda J, Hayden P, McLornan D, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(7):1593-1602.

Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia
Bazarbachi A, Labopin M, Blaise D, Forcade E, Socié G, Berceanu A, Angelucci E, Bulabois C, Kröger N, Rambaldi A, Ceballos P, Mielke S, El Cheikh J, Yakoub-Agha I, Savani B, Spyridonidis A, Nagler A, Mohty M
BONE MARROW TRANSPL. 2021;56(3):622-634.

Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia
Bazarbachi A, Labopin M, Kröger N, Brecht A, Blaise D, Clausen J, Fanin R, Einsele H, Cavanna L, Itäla-Remes M, Bulabois C, Kündgen L, Martin H, Schmid C, Wagner-Drouet E, Alakel N, Bazarbachi A, Savani B, Nagler A, Mohty M
CL LYMPH MYELOM LEUK. 2021;21(12):831-840.

Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)
Beksac M, Kröger N, Byrne J, Ganser A, Yeğin Z, Schönland S
BONE MARROW TRANSPL. 2021;56(3):529-531.

Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
Brehm T, Heyer A, Roedl K, Jarczak D, Nierhaus A, Nentwich M, van der Meirschen M, Schultze A, Christner M, Fiedler W, Kröger N, Huber T, Klose H, Sterneck M, Jordan S, Kreuels B, Schmiedel S, Addo M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J
J CLIN MED. 2021;10(11):.

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Bruno B, Wäsch R, Engelhardt M, Gay F, Giaccone L, D'Agostino M, Rodríguez-Lobato L, Danhof S, Gagelmann N, Kröger N, Popat R, Van de Donk N, Terpos E, Dimopoulos M, Sonneveld P, Einsele H, Boccadoro M
HAEMATOLOGICA. 2021;106(8):2054-2065.

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
Christopeit M, Reichard M, Niederwieser C, Massoud R, Klyuchnikov E, Haase N, Wolschke C, Ayuk F, Heidenreich S, Kröger N
BONE MARROW TRANSPL. 2021;56(6):1478-1481.

Evaluation of the Robustness of Therapeutic Drug Monitoring Coupled with Bayesian Forecasting of Busulfan with Regard to Inaccurate Documentation
Dadkhah A, Alihodzic D, Broeker A, Kröger N, Langebrake C, Wicha S
PHARM RES-DORDR. 2021;38(10):1721-1729.

Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program
El Fakih R, Greinix H, Koh M, Shaw B, Mohty M, Al Nahedh M, Saber W, Kharfan-Dabaja M, Perales M, Savani B, Majhail N, Passweg J, Sureda A, Ahmed S, Gluckman E, Riches M, El-Jawahri A, Rondelli D, Srivastava A, Faulkner L, Atsuta Y, Ballen K, Rasheed W, Okamoto S, Seber A, Chao N, Kröger N, Kodera Y, Szer J, Hashmi S, Horowitz M, Weisdorf D, Niederwieser D, Aljurf M
TRANSPL CELL THER. 2021;27(3):267.e1-267.e5.

A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation
Gagelmann N, Badbaran A, Beelen D, Salit R, Stölzel F, Rautenberg C, Becker H, Radujkovic A, Panagiota V, Bogdanov R, Christopeit M, Park Y, Nibourel O, Luft T, Koldehoff M, Corsten M, Heuser M, Finke J, Kobbe G, Platzbecker U, Robin M, Scott B, Kröger N
BLOOD ADV. 2021;5(6):1760-1769.

Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia
Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, Platzbecker U, Ditschkowski M, Schroeder T, Koldehoff M, Heuser M, Kobbe G, Beelen D, Germing U, Kröger N
BIOL BLOOD MARROW TR. 2021;27(1):95.e1-95.e4.

Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
Gagelmann N, Eikema D, de Wreede L, Rambaldi A, Iacobelli S, Koster L, Caillot D, Blaise D, Remémyi P, Bulabois C, Passweg J, Leleu X, Zver S, Kobbe G, Ljungman P, Chevallier P, Ringhoffer M, Martin M, Salmenniemi U, Poiré X, Lenhoff S, Pioltelli P, Mordini N, Delforge M, Garderet L, Schönland S, Yakoub-Agha I, Kröger N
BONE MARROW TRANSPL. 2021;56(1):210-217.

Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?
Gagelmann N, Kröger N
HAEMATOLOGICA. 2021;106(7):1794-1804.

The role of novel agents for consolidation after autologous transplantation in newly diagnosed multiple myeloma: a systematic review
Gagelmann N, Kröger N
ANN HEMATOL. 2021;100(2):405-419.

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kröger N
FRONT IMMUNOL. 2021;12:.

Conditioning intensity before allogeneic haematopoietic stem cell transplantation: a quality control audit
Gratwohl A, Passweg J, Baldomero H, Orchard K, Kröger N, Snowden J
BRIT J HAEMATOL. 2021;192(6):e151-e154.

Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study
Greenfield D, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, Cortelezzi A, Lupo-Stangellini M, Özkurt Z, Arat M, Metzner B, Turlure P, Rovo A, Socié G, Mohty M, Nagler A, Kröger N, Dreger P, Labopin M, Han T, Tichelli A, Duarte R, Basak G, Snowden J
BONE MARROW TRANSPL. 2021;56(11):2820-2825.

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
Häußler V, Ufer F, Pöttgen J, Wolschke C, Friese M, Kröger N, Heesen C, Stellmann J
ANN CLIN TRANSL NEUR. 2021;8(6):1269-1278.

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
Hayden P, Eikema D, de Wreede L, Koster L, Kröger N, Einsele H, Minnema M, Dominietto A, Potter M, Passweg J, Bermúdez A, Nguyen-Quoc S, Platzbecker U, Tischer J, Ciceri F, Veelken J, Ljungman P, Schaap N, Forcade E, Carella A, Gandemer V, Arcese W, Bloor A, Olivieri A, Vincent L, Beksac M, Schönland S, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(10):2367-2381.

Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT
Heinicke T, Labopin M, Polge E, Stelljes M, Ganser A, Tischer J, Brecht A, Kröger N, Beelen D, Scheid C, Bethge W, Dreger P, Bunjes D, Wagner E, Platzbecker U, Savani B, Nagler A, Mohty M
LEUKEMIA LYMPHOMA. 2021;62(2):399-409.

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation
Hernández-Boluda J, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau I, Niittyvuopio R, Finke J, Cornelissen J, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I
LEUKEMIA. 2021;35(1):215-224.

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Hernández-Boluda J, Pereira A, Kröger N, Cornelissen J, Beelen D, de Witte M, Wilson K, Platzbecker U, Sengeloev H, Blaise D, Einsele H, Sockel K, Krüger W, Lenhoff S, Salaroli A, Martin H, García-Gutiérrez V, Pavone V, Alvarez-Larrán A, Raya J, Zinger N, Gras L, Hayden P, Czerw T, P McLornan D, Yakoub-Agha I
AM J HEMATOL. 2021;96(10):1186-1194.

Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Kharfan-Dabaja M, Labopin M, Brissot E, Kroger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, Ganser A, Stelljes M, Edinger M, Savani B, Ruggeri A, Sanz J, Nagler A, Mohty M
BRIT J HAEMATOL. 2021;193(3):592-601.

Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia
Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2021;27(10):841-850.

Role of pre-transplant MRD level detected by flow cytometry in recipients of allogeneic stem cell transplantation with AML
Klyuchnikov E, Christopeit M, Badbaran A, Bacher U, Fritsche-Friedland U, von Pein U, Wolschke C, Kröger N
EUR J HAEMATOL. 2021;106(5):606-615.

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
Kröger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, Robin M, Vrhovac R, Helbig G, Sockel K, Conneally E, Rubio M, Beguin Y, Finke J, Bernasconi P, Morozova E, Clausen J, von dem Borne P, Schaap N, Schroyens W, Patriarca F, Di Renzo N, Yeğin Z, Hayden P, McLornan D, Yakoub-Agha I
LEUKEMIA. 2021;35(12):3551-3560.

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)
Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk R, Wolf D, Stadler M, Kobbe G, Wulf G, Bug G, Schäfer-Eckart K, Scheid C, Nolte F, Krönke J, Stelljes M, Beelen D, Heinzelmann M, Haase D, Buchner H, Bleckert G, Giagounidis A, Platzbecker U
J CLIN ONCOL. 2021;39(30):3318-3327.

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
Lawless S, Sbianchi G, Morris C, Iacobelli S, Bosman P, Blaise D, Reményi P, Byrne J, Mayer J, Apperley J, Lund J, Kobbe G, Schaap N, Isaksson C, Lenhoff S, Basak G, Touzeau C, Wilson K, González Muñiz S, Scheid C, Browne P, Anagnostopoulos A, Rambaldi A, Jantunen E, Kröger N, Schönland S, Yakoub-Agha I, Garderet L
CL LYMPH MYELOM LEUK. 2021;21(10):686-693.

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani M, Apperley J, Berceanu A, Bofarull R, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox M, Grassi A, Jimenez M, Demir S, Kwon M, Llamas C, Lorenzo J, Mielke S, Orchard K, Porras R, Vallisa D, Xhaard A, Knelange N, Cedillo A, Kröger N, Piñana J, Styczynski J
LEUKEMIA. 2021;35(10):2885-2894.

Correction: The challenge of COVID-19 and hematopoietic cell transplantation: EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Ljungman P, Mikulska M, de la Camara R, Basak G, Chabannon C, Corbacioglu S, Duarte R, Dolstra H, Lankester A, Mohty M, Montoto S, Murray J, de Latour R, Snowden J, Yakoub-Agha I, Verhoeven B, Kröger N, Styczynski J
BONE MARROW TRANSPL. 2021;56(3):755.

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia
Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, Kröger N, Cornelissen J, Lovira M, Meijer E, Vitek A, Elmaagacli A, Blaise D, Ruggeri A, Chabannon C, Nagler A, Mohty M
LEUKEMIA. 2021;35(2):585-594.

Anti-Thymocyte Globulin Treatment Augments 1,25-Dihydroxyvitamin D3 Serum Levels in Patients Undergoing Hematopoietic Stem Cell Transplantation
Matos C, Peter K, Weich L, Peuker A, Schoenhammer G, Roider T, Ghimire S, Babl N, Decking S, Güllstorf M, Kröger N, Hammon K, Herr W, Stark K, Heid I, Renner K, Holler E, Kreutz M
FRONT IMMUNOL. 2021;12:.

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis
McLornan D, Eikema D, Czerw T, Kröger N, Koster L, Reinhardt H, Angelucci E, Robin M, Bornhäuser M, Passweg J, Clark A, Vydra J, Blau I, Niittyvuopio R, Platzbecker U, Cornelissen J, Chevallier P, Srour M, Stamatovic D, Martinez-Lopez J, de Wreede L, Hayden P, Hernández-Boluda J, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(9):2160-2172.

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2021;56(10):2617.

Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)
Mohseny A, Eikema D, Neven B, Kröger N, Shaw P, Damaj G, Dalle J, Bosman P, Delehaye F, Lankester A, Smiers F, Peffault de Latour R
J PEDIAT HEMATOL ONC. 2021;43(7):e1025-e1029.

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
Nabergoj M, Mauff K, Robin M, Kröger N, Angelucci E, Poiré X, Passweg J, Radujkovic A, Platzbecker U, Robinson S, Rambaldi A, Petersen S, Stölzel F, Stelljes M, Ciceri F, Mayer J, Ladetto M, de Wreede L, Koster L, Hayden P, Czerw T, Hernández-Boluda J, McLornan D, Chalandon Y, Yakoub-Agha I
BONE MARROW TRANSPL. 2021;56(8):1944-1952.

Comparison of Haploidentical Bone Marrow versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Posttransplant Cyclophosphamide in Patients with Acute Leukemia
Nagler A, Labopin M, Dholaria B, Angelucci E, Afanasyev B, Cornelissen J, Sica S, Meijer E, Ciceri F, Van Gorkom G, Kröger N, Martin H, Pioltelli P, Risitano A, Canaani J, Savani B, Sanz J, Mohty M
CLIN CANCER RES. 2021;27(3):843-851.

Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome
Niederwieser C, Kröger N
BEST PRACT RES CL HA. 2021;34(4):.

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
Niederwieser C, Morozova E, Zubarovskaya L, Zabelina T, Klyuchnikov E, Janson D, Wolschke C, Christopeit M, Ayuk F, Moiseev I, Afanasyev B, Kröger N
BONE MARROW TRANSPL. 2021;56(11):2834-2841.

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q
Panagiota V, Meggendorfer M, Kubasch A, Gabdoulline R, Krönke J, Mies A, Shahswar R, Kandziora C, Klement P, Schiller J, Göhring G, Haferlach C, Ganster C, Shirneshan K, Gutermuth A, Thiede C, Germing U, Schroeder T, Kobbe G, Klesse S, Koenecke C, Schlegelberger B, Kröger N, Haase D, Döhner K, Sperr W, Valent P, Ganser A, Thol F, Haferlach T, Platzbecker U, Heuser M
AM J HEMATOL. 2021;96(6):E207-E210.

Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
Passweg J, Baldomero H, Chabannon C, Basak G, de la Cámara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester A, Mohty M, Peffault de Latour R, Snowden J, Yakoub-Agha I, Kröger N
BONE MARROW TRANSPL. 2021;56(7):1651-1664.

Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT
Peric Z, Peczynski C, Polge E, Kröger N, Sengeloev H, Radujkovic A, Helbig G, Russell N, Bunjes D, Socié G, Potter V, Beelen D, Crawley C, Bloor A, Finke J, Schoemans H, Penack O, Snowden J, Koenecke C, Basak G
BONE MARROW TRANSPL. 2021;56(12):3084-3087.

1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation
Peter K, Siska P, Roider T, Matos C, Bruns H, Renner K, Singer K, Weber D, Güllstorf M, Kröger N, Wolff D, Herr W, Ayuk F, Holler E, Stark K, Heid I, Kreutz M
BONE MARROW TRANSPL. 2021;56(2):419-433.

The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)
Poiani M, Labopin M, Battipaglia G, Beelen D, Tischer J, Finke J, Brecht A, Forcade E, Ganser A, Passweg J, Labussiere-Wallet H, Yakoub-Agha I, Schäfer-Eckart K, Kroeger N, Guffroy B, Ruggeri A, Esteve J, Nagler A, Mohty M
AM J HEMATOL. 2021;96(1):40-50.

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)
Polverelli N, Mauff K, Kröger N, Robin M, Beelen D, Beauvais D, Chevallier P, Mohty M, Passweg J, Rubio M, Maertens J, Finke J, Bornhäuser M, Vrhovac R, Helbig G, Mear J, Castagna L, Reményi P, Angelucci E, Karakasis D, Rifòn J, Sirait T, Russo D, de Wreede L, Czerw T, Hernández-Boluda J, Hayden P, McLornan D, Yakoub-Agha I
AM J HEMATOL. 2021;96(1):69-79.

Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19
Roedl K, Heidenreich S, Pfefferle S, Jarczak D, Urbanowicz T, Nörz D, Aepfelbacher M, Kröger N, Kluge S, Lütgehetmann M, Christopeit M, Wichmann D
AM J RESP CRIT CARE. 2021;203(2):242-245.

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
Rosiñol L, Beksac M, Zamagni E, Van de Donk N, Anderson K, Badros A, Caers J, Cavo M, Dimopoulos M, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle R, Leal da Costa F, Leleu X, Lentzsch S, Mateos M, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani S, Vanderkerken K, Vesole D, Waage A, Zweegman S, Richardson P, Bladé J
BRIT J HAEMATOL. 2021;194(3):496-507.

Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation
Sahebi F, Eikema D, Koster L, Kroger N, Meijer E, van Doesum J, Rovira M, Koc Y, Angelucci E, Blaise D, Sammassimo S, McDonald A, Arroyo C, Sanchez J, Forcade E, Castagna L, Stölzel F, Sanz J, Tischer J, Ciceri F, Valcarcel D, Proia A, Hayden P, Beksac M, Yakoub-Agha I, Schönland S
TRANSPL CELL THER. 2021;27(12):999.e1-999.e10.

Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT
Sanz J, Galimard J, Labopin M, Afanasyev B, Sergeevich M, Angelucci E, Kröger N, Koc Y, Ciceri F, Diez-Martin J, Arat M, Sica S, Rovira M, Aljurf M, Tischer J, Savani B, Ruggeri A, Nagler A, Mohty M
J HEMATOL ONCOL. 2021;14(1):84.

Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)
Saraceni F, Labopin M, Forcade E, Kröger N, Socié G, Niittyvuopio R, Cornelissen J, Labussière-Wallet H, Blaise D, Choi G, Byrne J, Guillerm G, Marchand T, Esteve J, Bazarbachi A, Savani B, Olivieri A, Nagler A, Mohty M
CANCER MED-US. 2021;10(1):23-33.

Corrigendum: Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede L, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee S, Kröger N, Hsu K, Schmidt A, Yakoub-Agha I, Robin M
FRONT IMMUNOL. 2021;12:813838.

Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party
Schetelig J, Chevallier P, van Gelder M, Hoek J, Hermine O, Chakraverty R, Browne P, Milpied N, Malagola M, Socié G, Delgado J, Deconinck E, Damaj G, Maury S, Beelen D, Quoc S, Shankara P, Brecht A, Mayer J, Hunault-Berger M, Bittenbring J, Thieblemont C, Lepretre S, Baldauf H, de Wreede L, Tournilhac O, Yakoub-Agha I, Kröger N, Dreger P
BONE MARROW TRANSPL. 2021;56(3):605-613.

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
Schetelig J, Hoek J, Stilgenbauer S, Middeke J, Andersen N, Fox C, Lenhoff S, Volin L, Shimoni A, Schroyens W, van Gelder M, Bunjes D, van Biezen A, Baldauf H, de Wreede L, Tournilhac O, Kröger N, Yakoub-Agha I, Dreger P
BONE MARROW TRANSPL. 2021;56(3):692-695.

Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca F, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf G, Van Gorkom G, Mayer J, Orvain C, Bourhis J, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden P, Yakoub-Agha I, Montoto S, Dreger P
BONE MARROW TRANSPL. 2021;56(12):.

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT
Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti G, Ciceri F, Bethge W, Volin L, Blaise D, Ganser A, Luft T, Chevallier P, Schwerdtfeger R, Koster L, de Witte T, Kröger N, Nagler A, Yakoub-Agha I
BRIT J HAEMATOL. 2021;195(3):417-428.

Visions for a JACIE Quality Management System 4.0
Snowden J, McGrath E, Orchard K, Kröger N, Sureda A, Gratwohl A
BONE MARROW TRANSPL. 2021;56(12):2876-2881.

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Spanjaart A, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz C, Metafuni E, Martinez-Lopez J, Dignan F, Ribera J, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten M, Mielke S
LEUKEMIA. 2021;35(12):3585-3588.

HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation
Tsamadou C, Engelhardt D, Platzbecker U, Sala E, Valerius T, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Frank S, Neuchel C, Schrezenmeier H, Mytilineos J, Fuerst D
FRONT IMMUNOL. 2021;12:.

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT
Waidhauser J, Labopin M, Esteve J, Kröger N, Cornelissen J, Gedde-Dahl T, Van Gorkom G, Finke J, Rovira M, Schaap N, Petersen E, Beelen D, Bunjes D, Savani B, Schmid C, Nagler A, Mohty M
BONE MARROW TRANSPL. 2021;56(10):2445-2453.

Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Wolff D, Fatobene G, Rocha V, Kröger N, Flowers M
BONE MARROW TRANSPL. 2021;56(9):2079-2087.

2020

Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee
Algwaiz G, Aljurf M, Koh M, Horowitz M, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood W, Brazauskas R, Lehmann L, Pasquini M, Seber A, Lu P, Atsuta Y, Riches M, Perales M, Worel N, Okamoto S, Srivastava A, Chemaly R, Cordonnier C, Dandoy C, Wingard J, Kharfan-Dabaja M, Hamadani M, Majhail N, Waghmare A, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi S
BIOL BLOOD MARROW TR. 2020;26(12):2181-2189.

Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis
Atagunduz I, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2020;26(12):2279-2284.

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
Atagunduz I, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, Ayuk F, Kröger N
CANCERS. 2020;12(11):.

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
Atanackovic D, Yousef S, Shorter C, Tantravahi S, Steinbach M, Iglesias F, Sborov D, Radhakrishnan S, Chiron M, Miles R, Salama M, Kröger N, Luetkens T
LEUKEMIA. 2020;34(1):317-321.

Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A
Ayuk F, Fehse B, Janson D, Berger C, Riecken K, Kröger N
HAEMATOLOGICA. 2020;105(6):322-324.

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
Aziz M, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen Y, Choe H, Etra A, Gergoudis S, Hartwell M, Hexner E, Hogan W, Kitko C, Kowalyk S, Kröger N, Merli P, Morales G, Nakamura R, Ordemann R, Pulsipher M, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara J, Levine J
LEUKEMIA. 2020;34(7):1898-1906.

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
Badbaran A, Berger C, Riecken K, Kruchen A, Geffken M, Müller I, Kröger N, Ayuk F, Fehse B
CANCERS. 2020;12(7):.

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
Baron F, Galimard J, Labopin M, Yakoub-Agha I, Niittyvuopio R, Kroger N, Griskevicius L, Wu D, Forcade E, Richard C, Aljurf M, Helbig G, Labussière-Wallet H, Mohty M, Nagler A
HAEMATOLOGICA. 2020;105(4):1138-1146.

Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT
Baron F, Labopin M, Savani B, Beohou E, Niederwieser D, Eder M, Potter V, Kröger N, Beelen D, Socié G, Itälä-Remes M, Bornhäuser M, Mohty M, Nagler A
BRIT J HAEMATOL. 2020;188(3):428-437.

Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party
Bazarbachi A, Al Hamed R, Labopin M, Afanasyev B, Hamladji R, Beelen D, Eder M, Scheid C, Wu D, Bunjes D, Stepensky P, Tischer J, Kröger N, Peric Z, Aljurf M, Giebel S, Nagler A, Mohty M
BONE MARROW TRANSPL. 2020;55(3):595-602.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel
Bonifazi F, Rubio M, Bacigalupo A, Boelens J, Finke J, Greinix H, Mohty M, Nagler A, Passweg J, Rambaldi A, Socie G, Solano C, Walker I, Barosi G, Kröger N
BONE MARROW TRANSPL. 2020;55(6):1093-1102.

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Röllig C, Wollmer E, Wäsch R, Bornhäuser M, Berg T, Lang F, Ehninger G, Serve H, Zeiser R, Wagner E, Kröger N, Wolschke C, Schleuning M, Götze K, Schmid C, Crysandt M, Eßeling E, Wolf D, Wang Y, Böhm A, Thiede C, Haferlach T, Michel C, Bethge W, Wündisch T, Brandts C, Harnisch S, Wittenberg M, Hoeffkes H, Rospleszcz S, Burchardt A, Neubauer A, Brugger M, Strauch K, Schade-Brittinger C, Metzelder S
J CLIN ONCOL. 2020;38(26):2993-3002.

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon M, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub Agha I, Kröger N, Robin M
BIOL BLOOD MARROW TR. 2020;26(3):451-457.

Clonal Evolution after Allogeneic Hematopoietic Stem Cell Transplantation
Christopeit M, Badbaran A, Alawi M, Flach J, Fehse B, Kröger N
BIOL BLOOD MARROW TR. 2020;26(7):e167-e170.

The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study
Cowan A, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A, Greinix H, Koh M, Worel N, Libby E, Pasquini M, Galeano S, Saber W, Iida M, Jaimovich G, Rolon J, Kodera Y, Benakli M, Nosa B, Elhaddad A, Szer J, Passweg J, Kroeger N, Weisdorf D, Niederwieser D
BIOL BLOOD MARROW TR. 2020;26(12):2372-2377.

Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1
Eberhard J, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopeit M, Kröger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Hütter G, Kuball J, Martinez-Laperche C, Balsalobre P, Kwon M, Díez-Martín J, Nijhuis M, Wensing A, Martinez-Picado J, Schulze Zur Wiesch J, Sáez-Cirión A
SCI TRANSL MED. 2020;12(542):.

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
Fehse B, Badbaran A, Berger C, Sonntag T, Riecken K, Geffken M, Kröger N, Ayuk F
MOL THER-METH CLIN D. 2020;16:172-178.

Obituary Rolf Neth 1926-2020
Fehse B, Kröger N, Stocking C, Zander A
EXP HEMATOL. 2020;85:1-2.

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Fenk R, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kroger N, Boquoi A, Lopez D, Gerrlich C, Baier J, Liesenjohann S, Hauck K, Savickaite I, Mai E, Aul C, Strapatsas J, Dienst A, Kondakci M, Haas R, Kobbe G
CLIN CANCER RES. 2020;26(22):5879-5886.

Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT
Frankiewicz A, Peczynski C, Giebel S, Harrington A, Socié G, Niederwieser D, Scheid C, Bornhäuser M, Kröger N, Elmaagacli A, Afanasyev B, Dreger P, Rössig C, Blaise D, Kratz C, Yakoub-Agha I, Kremens B, Niemeyer C, Wulf G, Blau I, Penack O, Greinix H, Basak G
FRONT IMMUNOL. 2020;11:1537.

B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma
Gagelmann N, Ayuk F, Atanackovic D, Kröger N
EUR J HAEMATOL. 2020;104(4):318-327.

Double Counting of Patients in Meta-analyses of Observational Studies-Reply
Gagelmann N, Kröger N
JAMA ONCOL. 2020;6(5):787-788.

Development of CAR-T cell therapies for multiple myeloma
Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk F, Fehse B, Kröger N
LEUKEMIA. 2020;34(9):2317-2332.

Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group
Giardino S, de Latour R, Aljurf M, Eikema D, Bosman P, Bertrand Y, Tbakhi A, Holter W, Bornhäuser M, Rössig C, Burkhardt B, Zecca M, Afanasyev B, Michel G, Ganser A, Alseraihy A, Ayas M, Uckan-Cetinkaya D, Bruno B, Patrick K, Bader P, Itälä-Remes M, Rocha V, Jubert C, Diaz M, Shaw P, Junior L, Locatelli F, Kröger N, Faraci M, Pierri F, Lanino E, Miano M, Risitano A, Robin M, Dufour C
AM J HEMATOL. 2020;95(7):809-816.

Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN
Gleitz H, Dugourd A, Leimkühler N, Snoeren I, Fuchs S, Menzel S, Ziegler S, Kröger N, Triviai I, Büsche G, Kreipe H, Banjanin B, Pritchard J, Hoogenboezem R, Bindels E, Schumacher N, Rose-John S, Elf S, Saez-Rodriguez J, Kramann R, Schneider R
BLOOD. 2020;136(18):2051-2064.

Implementation analysis of patient reported outcomes (PROs) in oncological routine care: an observational study protocol
Görlach M, Schrage T, Bokemeyer C, Kröger N, Müller V, Petersen C, Betz C, Krüll A, Schulz H, Bleich C
HEALTH QUAL LIFE OUT. 2020;18(1):3.

Survival following allogeneic transplant in patients with myelofibrosis
Gowin K, Ballen K, Ahn K, Hu Z, Ali H, Arcasoy M, Devlin R, Coakley M, Gerds A, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall A, Luber K, Masarova L, Michaelis L, Patches S, Pariser A, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos B, Bacher U, Bashey A, Beitinjaneh A, Cerny J, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Gadalla S, Ganguly S, Grunwald M, Hashmi S, Kharfan-Dabaja M, Kindwall-Keller T, Kröger N, Lazarus H, Liesveld J, Litzow M, Marks D, Nathan S, Nishihori T, Olsson R, Pawarode A, Rowe J, Savani B, Savoie M, Seo S, Solh M, Tamari R, Verdonck L, Yared J, Alyea E, Popat U, Sobecks R, Scott B, Nakamura R, Mesa R, Saber W
BLOOD ADV. 2020;4(9):1965-1973.

Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT
Gran C, Wang J, Nahi H, Koster L, Gahrton G, Einsele H, Niittyvoupio R, Edinger M, Beelen D, Ciceri F, Bornhäuser M, Finke J, de Wreede L, Ljungman P, Mielke S, Tischer J, Garderet L, Schönland S, Yakoub-Agha I, Kröger N
BRIT J HAEMATOL. 2020;189(5):e213-e217.

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Hambach J, Riecken K, Cichutek S, Schütze K, Albrecht B, Petry K, Röckendorf J, Baum N, Kröger N, Hansen T, Schuch G, Haag F, Adam G, Fehse B, Bannas P, Koch-Nolte F
CELLS-BASEL. 2020;9(2):.

Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP
Hayden P, Iacobelli S, Pérez-Simón J, van Biezen A, Minnema M, Niittyvuopio R, Schönland S, Meijer E, Blaise D, Milpied N, Márquez-Malaver F, Veelken J, Maertens J, Michallet M, Cammenga J, N'Guyen S, Niederwieser D, Hunault-Berger M, Bourhis J, Passweg J, Bermudez A, Chalandon Y, Yakoub-Agha I, Garderet L, Kröger N
EUR J HAEMATOL. 2020;104(3):181-189.

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects
Jansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, Salwender H, Einsele H, Kröger N, Beelen D, Dreger P, Goldschmidt H, Brenner H
LEUKEMIA LYMPHOMA. 2020;61(10):2365-2374.

Preventing Graft-Versus-Host Disease Without Losing Graft-Versus-Leukemia Effect After Allogeneic Stem-Cell Transplantation
Kröger N
J CLIN ONCOL. 2020;38(29):3357-3360.

Major central nervous system complications after allogeneic stem cell transplantation: a large retrospective study on 888 consecutive adult patients
Mannina D, Berneking L, Both A, Timm W, Urbanowicz T, Wolschke C, Ayuk F, Fischer N, Fiehler J, Grzyska U, Rösner S, Choe C, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(6):722-730.

Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT
McLornan D, Malpassuti V, Lippinkhof-Kozijn A, Potter V, Beelen D, Bunjes D, Sengeloev H, Radujkovic A, Passweg J, Chalandon Y, Kröger N, Wulf G, Johansson J, Ciceri F, Bornhäuser M, Holler E, Guffroy B, Martin S, Neubauer A, Gramatski M, Robin M, Iacobelli S, Hayden P, Hernández Boluda J, Czerw T, Yakoub-Agha I
BRIT J HAEMATOL. 2020;190(3):437-441.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
Michallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox C, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J
BONE MARROW TRANSPL. 2020;55(5):884-890.

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2020;55(12):2286-2293.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Morris C, Chabannon C, Masszi T, Russell N, Nahi H, Kobbe G, Krejci M, Auner H, Pohlreich D, Hayden P, Basak G, Lenhoff S, Schaap N, van Biezen A, Knol C, Iacobelli S, Liu Q, Celanovic M, Garderet L, Kröger N
BONE MARROW TRANSPL. 2020;55(2):356-366.

Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries
Muhsen I, Hashmi S, Niederwieser D, Kroeger N, Agrawal S, Pasquini M, Atsuta Y, Ballen K, Seber A, Saber W, Kharfan-Dabaja M, Rasheed W, Okamoto S, Khera N, Wood W, Koh M, Greinix H, Kodera Y, Szer J, Horowitz M, Weisdorf D, Aljurf M
BONE MARROW TRANSPL. 2020;55(4):837.

Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries
Muhsen I, Hashmi S, Niederwieser D, Kroeger N, Agrawal S, Pasquini M, Atsuta Y, Ballen K, Seber A, Saber W, Kharfan-Dabaja M, Rasheed W, Okamoto S, Khera N, Wood W, Koh M, Greinix H, Kodera Y, Szer J, Horowitz M, Weisdorf D, Aljurf M
BONE MARROW TRANSPL. 2020;55(4):698-707.

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis
Mytilineos D, Tsamadou C, Neuchel C, Platzbecker U, Bunjes D, Schub N, Wagner-Drouet E, Wulf G, Kröger N, Murawski N, Einsele H, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Dürholt M, Hertenstein B, Klein S, Ringhoffer M, Mueller C, Frank S, Schrezenmeier H, Fuerst D, Mytilineos J
FRONT IMMUNOL. 2020;11:.

Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation
Nagler A, Labopin M, Canaani J, Niittyvuopio R, Socié G, Kröger N, Itäla-Remes M, Yakoub-Agha I, Labussière-Wallet H, Gallego-Hernanz M, Deconinck E, Chevallier P, Finke J, Esteve J, Mohty M
AM J HEMATOL. 2020;95(10):1135-1141.

Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian B, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew I, Proietti M, Grimbacher B, Bulashevska A, Bhatt A, Brummer T, Clauditz T, Zabelina T, Kroeger N, Blazar B, Boerries M, Ayuk F, Zeiser R
BLOOD. 2020;136(12):1442-1455.

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression
Novak P, Klyuchnikov E, von Pein U, Güllstorf M, Christopeit M, Ayuk F, Geffken M, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2020;55(9):1817-1820.

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome
Novak P, Zabelina T, Wolschke C, Ayuk F, Christopeit M, Kröger N
BIOL BLOOD MARROW TR. 2020;26(11):2047-2052.

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus
Passweg J, Baldomero H, Chabannon C, Basak G, Corbacioglu S, Duarte R, Dolstra H, Lankester A, Mohty M, Montoto S, Peffault de Latour R, Snowden J, Styczynski J, Yakoub-Agha I, Kröger N
BONE MARROW TRANSPL. 2020;55(8):1604-1613.

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte R, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak G
LANCET HAEMATOL. 2020;7(2):e157-e167.

How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT
Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, Duarte R, Kröger N, Schoemans H, Koenecke C, Peric Z, Basak G
BLOOD ADV. 2020;4(24):6283-6290.

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party
Prata P, Eikema D, Afansyev B, Bosman P, Smiers F, Diez-Martin J, Arrais-Rodrigues C, Koc Y, Poiré X, Sirvent A, Kröger N, Porta F, Holter W, Bloor A, Jubert C, Ganser A, Tanase A, Ménard A, Pioltelli P, Pérez-Simón J, Ho A, Aljurf M, Russell N, Labussiere-Wallet H, Kerre T, Rocha V, Socié G, Risitano A, Dufour C, Peffault de Latour R
BONE MARROW TRANSPL. 2020;55(6):1050-1058.

FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Rodríguez-Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, Blau I, Kröger N, Kalhs P, Forcade E, Bunjes D, Spyridonidis A, Savani B, Nagler A, Mohty M
BIOL BLOOD MARROW TR. 2020;26(11):2165-2173.

Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1 year
Samek M, Iversen K, Belmar Campos C, Berneking L, Langebrake C, Wolschke C, Ayuk F, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(2):126-137.

Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede L, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee S, Kröger N, Hsu K, Schmidt A, Yakoub-Agha I, Robin M
FRONT IMMUNOL. 2020;11:.

Development of a Short Instrument for Measuring Health-Related Quality of Life in Oncological Patients for Clinical Use: Protocol for an Observational Study
Schrage T, Görlach M, Betz C, Bokemeyer C, Kröger N, Mueller V, Petersen C, Krüll A, Schulz H, Bleich C
JMIR RES PROTOC. 2020;9(7):e17854.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf J, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P
THERANOSTICS. 2020;10(6):2645-2658.

Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey
Sellner L, Schetelig J, Koster L, Choi G, Blaise D, Beelen D, Schianca F, Passweg J, Schanz U, Gyan E, Sora F, Kröger N, Wulf G, Van Gorkom G, Mayer J, Orvain C, Bourhis J, Jindra P, Potter V, Zallio F, Vandenberghe E, Robinson S, Hayden P, Yakoub-Agha I, Montoto S, Dreger P
BONE MARROW TRANSPL. 2020;55(12):2335-2338.

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT
Shem-Tov N, Peczynski C, Labopin M, Itälä-Remes M, Blaise D, Labussière-Wallet H, Socié G, Kröger N, Mielke S, Afanasyev B, Chevallier P, Tischer J, Helbig G, Jindra P, Peric Z, Giebel S, Mohty M, Nagler A
LEUKEMIA. 2020;34(1):283-292.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, McGrath E, Brook N, de Elvira C, Gordon D, Poirel H, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo J, Spellman S, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak G, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour R, Kroeger N, Brand R, de Wreede L, van Zwet E, Putter H
BONE MARROW TRANSPL. 2020;55(4):681-694.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, McGrath E, Brook N, de Elvira C, Gordon D, Poirel H, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo J, Spellman S, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak G, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour R, Kroeger N, Brand R, de Wreede L, van Zwet E, Putter H
BONE MARROW TRANSPL. 2020;55(4):838-839.

Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors
Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P, Averbuch D, Cesaro S, de la Camara R, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kuball J, Lankester A, Montoto S, Nagler A, Snowden J, Kröger N, Mohty M, Gratwohl A
BONE MARROW TRANSPL. 2020;55(1):126-136.

Fear of disease progression and relevant correlates in acute leukemia patients prior to allogeneic hematopoietic stem cell transplantation
Thiele S, Goebel S, Kröger N, Pedersen A
PSYCHO-ONCOLOGY. 2020;29(8):1248-1254.

Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
Tomaszewska A, Jagasia M, Beohou E, van der Werf S, Blaise D, Kanfer E, Milpied N, Reményi P, Ciceri F, Bourhis J, Chevallier P, Solano C, Socié G, Bruno B, Rambaldi A, Castagna L, Kröger N, Corradini P, Afanasyev B, Ladetto M, Niederwieser D, Scheid C, Sengeloev H, Kroschinsky F, Yakoub-Agha I, Schoemans H, Koenecke C, Penack O, Perić Z, Greinix H, Duarte R, Basak G
FRONT IMMUNOL. 2020;11:.

Evaluation of the Cost of Survivorship Care After Allogeneic Hematopoeitic Stem Cell Transplantation-An Analysis of 2 German Transplantation Centers
Wolff D, Bardak J, Edinger M, Klinger-Schindler U, Holler E, Lawitschka A, Schoemans H, Herr W, Kröger N, Ayuk Ayuketang F
FRONT PUBLIC HEALTH. 2020;8:572470.

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Yakoub-Agha I, Chabannon C, Bader P, Basak G, Bonig H, Ciceri F, Corbacioglu S, Duarte R, Einsele H, Hudecek M, Kersten M, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden J, Srour M, Styczynski J, Urbano-Ispizua A, Hayden P, Kröger N
HAEMATOLOGICA. 2020;105(2):297-316.

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner E, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi K, Socié G
NEW ENGL J MED. 2020;382(19):1800-1810.

2019

DAMIAN an open source bioinformatics tool for fast, systematic and cohort based analysis of microorganisms in diagnostic samples
Alawi M, Burkhardt L, Indenbirken D, Reumann K, Christopeit M, Kröger N, Lütgehetmann M, Aepfelbacher M, Fischer N, Grundhoff A
SCI REP-UK. 2019;9(1):16841.

"Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries"
Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, Hashmi S, Kröger N, Shaw B, Greinix H, Kharfan-Dabaja M, Foeken L, Seber A, Ahmed S, El-Jawahri A, Al-Awwami M, Atsuta Y, Pasquini M, Hanbali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Kodera Y, Horowitz M, Niederwieser D, El Fakih R
BONE MARROW TRANSPL. 2019;54(8):1179-1188.

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning
Andersen N, Bornhäuser M, Gramatzki M, Dreger P, Vitek A, Karas M, Michallet M, Moreno C, van Gelder M, Henseler A, de Wreede L, Schönland S, Kröger N, Schetelig J
J CANCER RES CLIN. 2019;145(11):2823-2834.

Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT)
Ayuk F, Bornhäuser M, Stelljes M, Zabelina T, Wagner E, Schmid C, Christopeit M, Guellstorf M, Kröger N, Bethge W
TRANSFUS MED HEMOTH. 2019;46(5):370-375.

Chancen und Risiken der CAR-T-Zell-Therapie
Ayuk F, Fehse B, Berger S, Riecken K, Kroger N
Hamb Ärztebl. 2019;73(10):30-32.

Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends
Baldomero H, Aljurf M, Zaidi S, Hashmi S, Ghavamzadeh A, Elhaddad A, Hamladji R, Ahmed P, Torjemane L, Abboud M, Tbakhi A, Khabori M, El Quessar A, Bazuaye N, Bekadja M, Adil S, Fahmy O, Ramzi M, Ibrahim A, Alseraihy A, Ben Abdejalil N, Sarhan M, Huneini M, Mahmal L, ElSolh H, Hussain F, Nassar A, Al-Hashmi H, Hamidieh A, Pasquini M, Kodera Y, Kröger N, Mohty M, Jaimovich G, Rolon J, Paulson K, Greinix H, Weisdorf D, Horowitz M, Nunez J, Gratwohl A, Passweg J, Koh M, Szer J, Niederwieser D, Novitzky N
BONE MARROW TRANSPL. 2019;54(3):402-417.

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, Sanz J, Stuhler G, Bosi A, Kröger N, Van Lint M, Ganser A, Forcade E, Mohty M, Gluckman E, Nagler A
BLOOD CANCER J. 2019;9(4):46.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg J, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M
BLOOD. 2019;134(11):892-899.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Herrera P, Sureda A, Carella A, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N
LANCET HAEMATOL. 2019;6(2):e89-e99.

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A
HAEMATOLOGICA. 2019;104(3):524-532.

Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socié G, Kröger N, Mohty M, Nagler A
J INTERN MED. 2019;285(4):407-418.

Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents
Chen Y, McCarthy P, Hahn T, Holstein S, Ueda M, Kröger N, Bishop M, de Lima M
BONE MARROW TRANSPL. 2019;54(4):497-507.

A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation
Cremers E, de Witte T, de Wreede L, Eikema D, Koster L, van Biezen A, Finke J, Socié G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziagkos D, Itälä-Remes M, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Ozkurt Z, Anagnostopoulos A, Jindra P, Robin M, Kröger N
LEUKEMIA LYMPHOMA. 2019;60(10):2404-2414.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years
Daghia G, Zabelina T, Zeck G, von Pein U, Christopeit M, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2019;103(4):370-378.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen N, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari M, Schaap M, Fox C, Kröger N, Montoto S, Schetelig J
BONE MARROW TRANSPL. 2019;54(1):44-52.

Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019
Duarte R, Labopin M, Bader P, Basak G, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery A, Kuball J, Lankester A, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden J, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M
BONE MARROW TRANSPL. 2019;54(10):1525-1552.

Prevention and treatment of relapse after stem cell transplantation by cellular therapies
Falkenburg F, Ruggiero E, Bonini C, Porter D, Miller J, Malard F, Mohty M, Kröger N, Kolb H
BONE MARROW TRANSPL. 2019;54(1):26-34.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Frick M, Chan W, Arends C, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau I, Ogawa S, Zemojtel T, Gerbitz A, Wagner E, Spriewald B, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F
J CLIN ONCOL. 2019;37(5):375-385.

Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis
Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, Bonifazi F, Meijer E, Itälä-Remes M, Marková M, Solano C, Kröger N
JAMA ONCOL. 2019;5(12):1739-1748.

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socié G, Beelen D, Triviai I, Badbaran A, Kröger N
BLOOD. 2019;133(20):2233-2242.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation
Gagelmann N, Eikema D, de Wreede L, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis J, Mohty M, Cornelissen J, Chevallier P, Bernasconi P, Stelljes M, Rohrlich P, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N
BIOL BLOOD MARROW TR. 2019;25(6):e204-e208.

Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Gagelmann N, Eikema D, Koster L, Caillot D, Pioltelli P, Lleonart J, Reményi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras R, Cahn J, Musso M, Poiré X, Fenk R, Itälä-Remes M, Pavone V, Fouillard L, Maertens J, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N
BIOL BLOOD MARROW TR. 2019;25(11):2134-2142.

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Gagelmann N, Eikema D, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange N, Niederwieser D, Friis L, Ehnninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen J, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N
HAEMATOLOGICA. 2019;104(5):929-936.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes
Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze K, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D
GENE CHROMOSOME CANC. 2019;58(10):689-697.

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia
Gratwohl A, Duarte R, Snowden J, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix H, Grath E, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R
ECLINICALMEDICINE. 2019;15:33-41.

Unklare Panzytopenie bei einem 52-jährigen Patienten
Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C
INTERNIST. 2019;60(8):867-870.

The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma
Holderried T, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D
BONE MARROW TRANSPL. 2019;54(10):1662-1667.

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party
Hübel K, Re A, Boumendil A, Finel H, Hentrich M, Robinson S, Wyen C, Michieli M, Kanfer E, Diez-Martin J, Balsalobre P, Vincent L, Schroyens W, Santasusana J, Kröger N, Schiel X, Cwynarski K, Esquirol A, Sousa A, Cattaneo C, Montoto S, Dreger P
BONE MARROW TRANSPL. 2019;54(10):1625-1631.

Prevention and Treatment of Relapse by Drugs
Kroger N
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 437-442.

Induction, Bridging, or Straight Ahead: The Ongoing Dilemma of Allografting in Advanced Myelodysplastic Syndrome
Kröger N
BIOL BLOOD MARROW TR. 2019;25(8):e247-e249.

Myeloproliferative Neoplasms
Kroger N, Chalandon Y
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 569 - 578.

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia
Kröger N, Eikema D, Köster L, Beelen D, de Wreede L, Finke J, Koenecke C, Niederwieser D, Bornhäuser M, Schoenland S, Potter V, Wolschke C, Maertens J, Theobald M, Kobbe G, Itälä-Remes M, Wulf G, Kahls P, Forcade E, Greinix H, Masszi T, Yakoub-Agha I, Chalandon Y, Robin M
BRIT J HAEMATOL. 2019;185(4):725-732.

Methods and role of minimal residual disease after stem cell transplantation
Ladetto M, Böttcher S, Kröger N, Pulsipher M, Bader P
BONE MARROW TRANSPL. 2019;54(5):681-690.

Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation
Mannina D, Gagelmann N, Badbaran A, Ditschkowski M, Bogdanov R, Robin M, Cassinat B, Heuser M, Shahswar R, Thol F, Beelen D, Kröger N
EUR J HAEMATOL. 2019;103(6):552-557.

Janus Kinase Inhibition for Graft-Versus-Host Disease:Current Status and Future Prospects: Current Status and Future Prospects
Mannina D, Kröger N
DRUGS. 2019;79(14):1499-1509.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis
Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein U, Janson D, Ayuk F, Kröger N
BRIT J HAEMATOL. 2019;186(3):484-489.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda J, Czerw T, Hayden P, Kröger N, Yakoub-Agha I
BIOL BLOOD MARROW TR. 2019;25(11):2167-2171.

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019: allogeneic stem cell transplantation for myelofibrosis in 2019
McLornan D, Yakoub-Agha I, Robin M, Chalandon Y, Harrison C, Kroger N
HAEMATOLOGICA. 2019;104(4):659-668.

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
Minnema M, Nasserinejad K, Hazenberg B, Hegenbart U, Vlummens P, Ypma P, Kröger N, Wu K, Kersten M, Schaafsma M, Croockewit S, de Waal E, Zweegman S, Tick L, Broijl A, Koene H, Bos G, Sonneveld P, Schönland S
HAEMATOLOGICA. 2019;104(11):2274-2282.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis
Palmer J, Kosiorek H, Wolschke C, Fauble V, Butterfield R, Geyer H, Scherber R, Dueck A, Gathany A, Mesa R, Kroger N
BIOL BLOOD MARROW TR. 2019;25(11):2267-2273.

The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
Passweg J, Baldomero H, Basak G, Chabannon C, Corbacioglu S, Duarte R, Kuball J, Lankester A, Montoto S, de Latour R, Snowden J, Styczynski J, Yakoub-Agha I, Arat M, Mohty M, Kröger N
BONE MARROW TRANSPL. 2019;54(10):1575-1585.

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
Pavlů J, Labopin M, Niittyvuopio R, Socié G, Yakoub-Agha I, Wu D, Remenyi P, Passweg J, Beelen D, Aljurf M, Kröger N, Labussière-Wallet H, Perić Z, Giebel S, Nagler A, Mohty M
J HEMATOL ONCOL. 2019;12(1):108.

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
Radujkovic A, Dietrich S, Blok H, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne J, Jindra P, Veelken J, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y
BIOL BLOOD MARROW TR. 2019;25(10):2008-2016.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
Raj K, Eikema D, McLornan D, Olavarria E, Blok H, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede L, Volin L, Koc Y, Diez-Martin J, Brossart P, Wolf D, Blaise D, Bartolomeo P, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N
BIOL BLOOD MARROW TR. 2019;25(3):522-528.

JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
Rao T, Hansen N, Hilfiker J, Rai S, Majewska J, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan T, Lane A, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić V, Skoda R
BLOOD. 2019;134(21):1832-1846.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
Rice C, Eikema D, Marsh J, Knol C, Hebert K, Putter H, Peterson E, Deeg H, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin J, Schaap N, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens J, Mufti G, Potter V, Pefault de la Tour R, Eapen M, Dufour C
BIOL BLOOD MARROW TR. 2019;25(3):488-495.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A
BIOL BLOOD MARROW TR. 2019;25(10):1975-1983.

Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis
Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis J, Chevallier P, Cornelissen J, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten H, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt Z, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N
HAEMATOLOGICA. 2019;104(6):1230-1236.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Robin M, de Wreede L, Wolschke C, Schetelig J, Eikema D, Van Lint M, Knelange N, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N
HAEMATOLOGICA. 2019;104(9):1782-1788.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon M, Verbeek M, Rambaldi A, Cornelissen J, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N
BIOL BLOOD MARROW TR. 2019;25(1):114-120.

Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults a survey by the Transplant Complications Working Party of the EBMT
Ruutu T, van der Werf S, van Biezen A, Backman J, Peczynski C, Kröger N, Mohty M, Nagler A, Montoto S, Langebrake C, Niederwieser D, Peric Z, Koenecke C, Duarte R, Basak G
BONE MARROW TRANSPL. 2019;54(12):2013-2019.

Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
Sahebi F, Garderet L, Kanate A, Eikema D, Knelange N, Alvelo O, Koc Y, Blaise D, Bashir Q, Moraleda J, Dreger P, Sanchez J, Ciurea S, Schouten H, Shah N, Verbeek M, Rösler W, Diez-Martin J, Schoenland S, D'Souza A, Kröger N, Hari P
BIOL BLOOD MARROW TR. 2019;25(2):335-342.

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Saraceni F, Labopin M, Brecht A, Kröger N, Eder M, Tischer J, Labussière-Wallet H, Einsele H, Beelen D, Bunjes D, Niederwieser D, Bochtler T, Savani B, Mohty M, Nagler A
J HEMATOL ONCOL. 2019;12(1):44.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
Schetelig J, de Wreede L, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti G, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N
LEUKEMIA. 2019;33(3):686-695.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT
Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis J, Marchand T, Reményi P, Cahn J, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J
ANN HEMATOL. 2019;98(7):1755-1763.

Frequency of lethal central nervous system neurotoxicity in patients undergoing allogeneic stem cell transplantation: a retrospective registry analysis
Schultze-Florey C, Peczynski C, de Marino I, Polge E, Socié G, Blaise D, Beelen D, Franke G, Kröger N, Stelljes M, Afanasyev B, Potter V, Gerbitz A, Schetelig J, Peric Z, Schoemans H, Koenecke C, Basak G
BONE MARROW TRANSPL. 2019 [Epub ahead of print].

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, Gramatzki M, Stelljes M, Blaise D, Stoelzel F, Chevallier P, Holler E, Fegueux N, Mohty M, Nagler A
BLOOD CANCER J. 2019;9(12):88.

Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis
Shouval R, Fein J, Labopin M, Kröger N, Duarte R, Bader P, Chabannon C, Kuball J, Basak G, Dufour C, Galimard J, Polge E, Lankester A, Montoto S, Snowden J, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A
LANCET HAEMATOL. 2019;6(11):e573-e584.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT
Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward K, Cordonnier C, de la Camara R, Averbuch D, Knelange N, Socié G, Chevallier P, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Maertens J, Petersen E, Nguyen-Quoc S, Veelken H, Schaap N, Passweg J, Michallet M, Fegueux N, Deconinck E, Russell N, Basak G, Bader P, Montoto S, Kröger N, Cesaro S
BONE MARROW TRANSPL. 2019;54(12):2060-2071.

Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
Sureda A, Dreger P, Bishop M, Kroger N, Porter D
BONE MARROW TRANSPL. 2019;54(1):17-25.

ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF
Triviai I, Zeschke S, Rentel J, Spanakis M, Scherer T, Gabdoulline R, Panagiota V, Thol F, Heuser M, Stocking C, Kröger N
LEUKEMIA. 2019;33(1):99-109.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)
Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema D, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P
BONE MARROW TRANSPL. 2019;54(9):1391-1398.

Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma
Ye R, Kundrapu S, Gerson S, Driscoll J, Beck R, Ali N, Landgren O, VanHeeckeren W, Luo G, Kroger N, Caimi P, De Lima M, Malek E
CL LYMPH MYELOM LEUK. 2019;19(5):e213-e220.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation
Zeiser R, Beelen D, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann J, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller L
BIOL BLOOD MARROW TR. 2019;25(4):e128-e140.

2018

Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party
Auner H, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell N, Apperley J, Pohlreich D, Browne P, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland S, Morris C, Garderet L, Kröger N
HAEMATOLOGICA. 2018;103(3):514-521.

Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation
Ayuketang F, Kroger N
2018. Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation. Ayuk F, Kröger N, Tichelli A (Hrsg.). 1.. Aufl. Uni-Med, .

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Ayuk F, Beelen D, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner E, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn P, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W
BIOL BLOOD MARROW TR. 2018;24(12):2558-2567.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R, Verstovsek S, Mesa R, Kiladjian J, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin M, Hasselbalch H, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G
LEUKEMIA. 2018;32(5):1057-1069.

Transplant results in adults with Fanconi anaemia
Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta P, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak G, Othman T, Halkes C, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano A, Ehninger G, Porcher R, Dufour C
BRIT J HAEMATOL. 2018;180(1):100-109.

Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects
Fuerst D, Frank S, Mueller C, Beelen D, Schetelig J, Niederwieser D, Finke J, Bunjes D, Kröger N, Neuchel C, Tsamadou C, Schrezenmeier H, Beyersmann J, Mytilineos J
HAEMATOLOGICA. 2018;103(9):1527-1534.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT
Gagelmann N, Eikema D, Iacobelli S, Koster L, Nahi H, Stoppa A, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden J, Itälä-Remes M, Musso M, van Biezen A, Garderet L, Kröger N
HAEMATOLOGICA. 2018;103(5):890-897.

Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
Gagelmann N, Ljungman P, Styczynski J, Kröger N
BIOL BLOOD MARROW TR. 2018;24(10):2101-2109.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson J, Bourhis J, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N
BIOL BLOOD MARROW TR. 2018;24(7):1372-1378.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5Q Deletion
Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti G, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2018;24(3):507-513.

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner H, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P
HAEMATOLOGICA. 2018;103(2):197-211.

Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, Kröger N, Petersen E, Van Lint M, Oneto R, Signori A, Bacigalupo A
BLOOD. 2018;131(17):1989-1992.

Prevention and treatment of relapse after stem cell transplantation with immunotherapy
Gökbuget N, Canaani J, Nagler A, Bishop M, Kröger N, Avigan D
BONE MARROW TRANSPL. 2018;53(6):664-672.

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation
Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, Maertens J, Cornelissen J, Milpied N, Stuhler G, Kröger N, Esteve J, Mohty M, Nagler A
BONE MARROW TRANSPL. 2018;53(6):683-691.

Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study
Hartung T, Sautier L, Scherwath A, Sturm K, Kröger N, Koch U, Mehnert A
ONCOL RES TREAT. 2018;41(11):697-701.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuk F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI INSIGHT. 2018;3(16):.

Improving Lentiviral Transduction of CD34(+) Hematopoietic Stem and Progenitor Cells
Hauber I, Beschorner N, Schrödel S, Chemnitz J, Kröger N, Hauber J, Thirion C
HUM GENE THER METHOD. 2018;29(2):104-113.

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma
Heinzelmann F, Bethge W, Beelen D, Stelljes M, Dreger P, Engelhard M, Finke J, Kröger N, Holler E, Bornhäuser M, Müller A, Haubitz I, Ottinger H
J CANCER RES CLIN. 2018;144(6):1173-1183.

Epidemiology and biology of relapse after stem cell transplantation
Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, Vago L, Kröger N
BONE MARROW TRANSPL. 2018;53(11):1379-1389.

Third International workshop on the biology, prevention, and treatment of relapse after stem cell transplantation
Kröger N, Bishop M, Giralt S, Wayne A
BONE MARROW TRANSPL. 2018;53(1):1-2.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C
BIOL BLOOD MARROW TR. 2018;24(10):2152-2156.

MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD
Major-Monfried H, Renteria A, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera Y, Hogan W, Wölfl M, Qayed M, Hexner E, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell M, Chaudhry M, Aziz M, Etra A, Yanik G, Kröger N, Weber D, Chen Y, Nakamura R, Rösler W, Kitko C, Harris A, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara J, Levine J
BLOOD. 2018;131(25):2846-2855.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Mathew N, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller T, Hanke K, Taromi S, Apostolova P, Illert A, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong G, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder S, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller L, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert J, Feger D, Wagner E, Cahn J, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller A, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin J, Henden A, Hill G, Kennedy G, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin R, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri M, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar B, Zeiser R
NAT MED. 2018;24(4):526.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Mathew N, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller T, Hanke K, Taromi S, Apostolova P, Illert A, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong G, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder S, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller L, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert J, Feger D, Wagner E, Cahn J, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller A, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin J, Henden A, Hill G, Kennedy G, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin R, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri M, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar B, Zeiser R
NAT MED. 2018;24(3):282-291.

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation
Mohty M, Duarte R, Kuball J, Bader P, Basak G, Bonini C, Carreras E, Chabannon C, Dufour C, Gennery A, Lankester A, Lanza F, Ljungman P, Montoto S, Nagler A, Snowden J, Styczynski J, Sureda A, Kröger N
BONE MARROW TRANSPL. 2018;53(12):1548-1552.

Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens
Oyekunle A, Shumilov E, Kostrewa P, Burchert A, Trümper L, Wuchter P, Wulf G, Bacher U, Kröger N
BIOL BLOOD MARROW TR. 2018;24(2):276-281.

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
Passweg J, Baldomero H, Bader P, Basak G, Bonini C, Duarte R, Dufour C, Kröger N, Kuball J, Lankester A, Montoto S, Nagler A, Snowden J, Styczynski J, Mohty M
BONE MARROW TRANSPL. 2018;53(9):1139-1148.

Oncogenic JAK2causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Prestipino A, Emhardt A, Aumann K, O'Sullivan D, Gorantla S, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi J, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl F, Minguet S, Miething C, Heidel F, Kröger N, Triviai I, Brummer T, Finke J, Illert A, Ruggiero E, Bonini C, Duyster J, Pahl H, Lane S, Hill G, Blazar B, von Bubnoff N, Pearce E, Zeiser R
SCI TRANSL MED. 2018;10:429.

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A
J INTERN MED. 2018;283(2):166-177.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
Robinson S, Boumendil A, Finel H, Peggs K, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P
BONE MARROW TRANSPL. 2018;53(5):617-624.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT
Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen J, Elmaagacli A, Itälä-Remes M, Blaise D, Meijer E, Koc Y, Milpied N, Schouten H, Kroeger N, Mohty M, Nagler A
J HEMATOL ONCOL. 2018;11(1):40.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Sahebi F, Iacobelli S, Sbianchi G, Koster L, Blaise D, Reményi P, Russell N, Ljungman P, Kobbe G, Apperley J, Trneny M, Krejci M, Wiktor-Jedrzejczak W, Sanchez J, Schaap N, Isaksson C, Lenhoff S, Browne P, Scheid C, Wilson K, Yakoub-Agha I, González Muñiz S, Schönland S, Morris C, Garderet L, Kröger N
BIOL BLOOD MARROW TR. 2018;24(5):930-936.

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A
J HEMATOL ONCOL. 2018;11(1):55.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation
Schmid C, de Wreede L, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen J, Blaise D, Gramatzki M, Milpied N, Yakub-Agha I, Mufti G, Rovira M, Arnold R, De Witte T, Robin M, Kröger N
HAEMATOLOGICA. 2018;103(2):237-245.

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N
EUR J HAEMATOL. 2018;101(3):305-317.

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
van Gorkom G, van Gelder M, Eikema D, Blok H, van Lint M, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller L, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N
BONE MARROW TRANSPL. 2018;53(3):255-263.

Acute hepatitis as a prequel to very severe aplastic anemia
Weiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M
Z GASTROENTEROL. 2018;56(1):51-54.

2017

Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Atanackovic D, Luetkens T, Radhakrishnan S, Kroger N
CURR CANCER DRUG TAR. 2017;17(9):839-845.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb H, Ganser A, Schäfer-Eckart K, Zander A, Bunjes D, Mielke S, Bethge W, Milpied N, Kalhs P, Blau I, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A
J HEMATOL ONCOL. 2017;10(1):130.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Bug G, Burchert A, Wagner E, Kröger N, Berg T, Güller S, Metzelder S, Wolf A, Hünecke S, Bader P, Schetelig J, Serve H, Ottmann O
LEUKEMIA. 2017;31(11):2523-2525.

CAR-T cells: the narrow path between hope and bankruptcy?
Chabannon C, Kuball J, Mcgrath E, Bader P, Dufour C, Lankester A, Basak G, Montoto S, Nagler A, Snowden J, Styczynski J, Duarte R, Kröger N, Mohty M
BONE MARROW TRANSPL. 2017;52(12):1588-1589.

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation
Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, McQuaker G, Schoenland S, Rambaldi A, Halaburda K, Rovira M, Sica S, Byrne J, Sanz R, Nagler A, van de Donk N, Sinisalo M, Cook M, Kröger N, De Witte T, Morris C, Garderet L
HAEMATOLOGICA. 2017;102(1):160-167.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti G, Fenaux P, Sanz G, Martino R, Alessandrino E, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht A, Ljungman P, Stauder R, Volin L, Deeg H, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N
BLOOD. 2017;129(13):1753-1762.

Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT
Esser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Schilling G, Götze H, Scherwath A
BONE MARROW TRANSPL. 2017;52(5):753-758.

Stability and priority of symptoms and symptom clusters among allogeneic HSCT patients within a 5-year longitudinal study
Esser P, Kuba K, Scherwath A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Götze H, Mehnert A
J PAIN SYMPTOM MANAG. 2017;54(4):493-500.

Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study
Esser P, Kuba K, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kröger N, Götze H, Mehnert A
J CANCER SURVIV. 2017;11(2):203-210.

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis
Gagelmann N, Ayuk F, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2017;23(12):2184-2191.

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting
Garderet L, Cook G, Auner H, Bruno B, Lokhorst H, Perez-Simon J, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N
LEUKEMIA LYMPHOMA. 2017;58(4):797-808.

Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances
Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P
BIOL BLOOD MARROW TR. 2017;23(7):1193-1202.

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation
Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix H, Mc Grath E, Kroeger N, Lanza F, Nagler A, Snowden J, Niederwieser D, Brand R
LEUKEMIA. 2017;31(8):1752-1759.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuketang F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI INSIGHT. 2017;2(3):e89798.

Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection
Heidenreich S, Kröger N
FRONT IMMUNOL. 2017;8:41.

Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Heidenreich S, Ziagkos D, de Wreede L, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen D, Tischer J, Nagler A, Glass B, Maertens J, Yáñez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachée P, Selleslag D, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2017;23(1):44-52.

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation
Heuser M, Gabdoulline R, Löffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Göhring G, Kreipe H, Germing U, Ganser A, Kröger N, Koenecke C, Thol F
ANN HEMATOL. 2017;96(8):1361-1372.

Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)
Hilken A, Langebrake C, Wolschke C, Kersten J, Rohde H, Nielsen P, Kröger N
ANN HEMATOL. 2017;96(8):1379-1388.

Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes
Kröger N
SEMIN HEMATOL. 2017;54(3):154-158.

Raising the bar for chronic GVHD trials
Kröger N
BLOOD. 2017;130(3):241-242.

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Kröger N, Iacobelli S, Franke G, Platzbecker U, Uddin R, Hübel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers G, Onida F, Dreger P, Pini M, Guidi S, Volin L, Günther A, Bethge W, Poiré X, Kobbe G, van Os M, Brand R, de Witte T
J CLIN ONCOL. 2017;35(19):2157-2164.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz M, Shahswar R, Ayuketang F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe H, Ganser A, Stocking C, Fehse B, Thol F, Heuser M
BIOL BLOOD MARROW TR. 2017;23(7):1095-1101.

Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany
Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kröger N, Götze H, Scherwath A
BONE MARROW TRANSPL. 2017;52(12):1651-1657.

Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)
Kuba K, Esser P, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kröger N, Götze H, Mehnert A
PSYCHO-ONCOLOGY. 2017;26(8):1164-1171.

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Locke F, Pidala J, Storer B, Martin P, Pulsipher M, Chauncey T, Jacobsen N, Kröger N, Walker I, Light S, Shaw B, Beato F, Laport G, Nademanee A, Keating A, Socie G, Anasetti C
BIOL BLOOD MARROW TR. 2017;23(3):405-411.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani B, Mohty M, Nagler A
BIOL BLOOD MARROW TR. 2017;23(2):278-284.

Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle: Examining Pieces of the Jigsaw Puzzle
Malek E, El-Jurdi N, Kröger N, de Lima M
FRONT ONCOL. 2017;7:287.

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
Marchetti M, Barosi G, Cervantes F, Birgegård G, Griesshammer M, Harrison C, Hehlmann R, Kiladjian J, Kröger N, McMullin M, Passamonti F, Vannucchi A, Barbui T
LEUKEMIA. 2017;31(4):882-888.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino E, Mufti G, Veelken J, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez A, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N
BONE MARROW TRANSPL. 2017;52(8):1107-1112.

Jon van Rood (1926-2017)
Mueller C, Bonini C, Foeken L, Chabannon C, Bondanza A, Fleischhauer K, Velardi A, Kröger N, Kuball J, Mohty M
BONE MARROW TRANSPL. 2017;52(12):1587.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger E, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch D, Grigoleit G
LEUKEMIA. 2017;31(10):2161-2171.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Onida F, de Wreede L, van Biezen A, Eikema D, Byrne J, Iori A, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson J, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N
BRIT J HAEMATOL. 2017;177(5):759-765.

In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
Oostvogels R, Uniken Venema S, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema M
BONE MARROW TRANSPL. 2017;52(9):1233-1240.

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2017;52(2):191-196.

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report
Passweg J, Baldomero H, Bader P, Bonini C, Duarte R, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden J, Styczynski J, Mohty M
BONE MARROW TRANSPL. 2017;52(6):811-817.

Haploidentical transplant in patients with myelodysplastic syndrome
Robin M, Porcher R, Ciceri F, van Lint M, Santarone S, Ehninger G, Blaise D, Güllbas Z, Gonzáles Muñiz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Díez-Martin J, Kanz L, Arroyo C, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kröger N
BLOOD ADV. 2017;1(22):1876-1883.

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N
BONE MARROW TRANSPL. 2017;52(2):209-215.

Erratum for: Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N
BONE MARROW TRANSPL. 2017;52(7):1081.

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis
Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kröger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte R
BONE MARROW TRANSPL. 2017;52(3):357-362.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen J, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken J, Ljungman P, Cahn J, Alessandrino E, de Witte T, Robin M, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1519-1525.

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)
Schetelig J, de Wreede L, Andersen N, Moreno C, van Gelder M, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Schaap N, Wagner E, Henseler A, van Biezen A, Bornhäuser M, Iacobelli S, Putter H, Schönland S, Kröger N
BRIT J HAEMATOL. 2017;178(4):521-533.

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
Schetelig J, de Wreede L, van Gelder M, Andersen N, Moreno C, Vitek A, Karas M, Michallet M, Machaczka M, Gramatzki M, Beelen D, Finke J, Delgado J, Volin L, Passweg J, Dreger P, Henseler A, van Biezen A, Bornhäuser M, Schönland S, Kröger N
BONE MARROW TRANSPL. 2017;52(4):552-560.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party
Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N
HAEMATOLOGICA. 2017;102(7):e271-e274.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
van Gelder M, de Wreede L, Bornhäuser M, Niederwieser D, Karas M, Anderson N, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen J, Yakoub-Agha I, Russell N, Finke J, Schoemans H, Vitek A, Urbano-Ispízua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J
BONE MARROW TRANSPL. 2017;52(3):372-380.

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, Stelljes M, Andersen N, Schaap N, Vitek A, Beelen D, Lindström V, Finke J, Passweg J, Eder M, Machaczka M, Delgado J, Krüger W, Raida L, Socié G, Jindra P, Afanasyev B, Wagner E, Chalandon Y, Henseler A, Schoenland S, Kröger N, Schetelig J
CL LYMPH MYELOM LEUK. 2017;17(10):667-675.e2.

Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuketang F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1526-1529.

2016

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
Alchalby H, Yunus D, Zabelina T, Ayuketang F, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1223-7.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
Bruno B, Auner H, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli R, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N
LEUKEMIA LYMPHOMA. 2016;57(6):1256-1268.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with MDS
Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuketang F, Kröger N
EUR J HAEMATOL. 2016;97(3):288-96.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(10):1391-1393.

Suspected encephalitis with Candida tropicalis and Fusarium detected by unbiased RNA sequencing
Christopeit M, Grundhoff A, Rohde H, Belmar-Campos C, Grzyska U, Fiehler J, Wolschke C, Kröger N, Fischer N
ANN HEMATOL. 2016;95(11):1919-1921.

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, Bourhis J, Sengelov H, Blaise D, Luft T, Hallek M, Kröger N, Nagler A, Mohty M
HAEMATOLOGICA. 2016;101(7):879-83.

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
Cremers E, van Biezen A, de Wreede L, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kröger N, de Witte T
ANN HEMATOL. 2016;95(12):1971-1978.

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis
Derlin T, Alchalby H, Bannas P, Laqmani A, Ayuketang F, Triviai I, Kreipe H, Bengel F, Kröger N
J NUCL MED. 2016;57(10):1556-1559.

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study
Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb H, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N
ANN HEMATOL. 2016;95(6):967-72.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment
Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer H, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer J, Ho A, Wilhelm M, Goebeler M, Lindemann H, Bormann M, Hertenstein B, Schlimok G, Baerlocher G, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld D, Kolb H, Büsche G, Haferlach C, Schnittger S, Müller M, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R
LEUKEMIA. 2016;30(3):562-9.

Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis
Hussein K, Stucki-Koch A, Alchalby H, Triviai I, Kröger N, Kreipe H
BIOL BLOOD MARROW TR. 2016;22(4):664-650.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party
Koenecke C, Heim D, van Biezen A, Heuser M, Aljurf M, Kyrcz-Krzemien S, Volin L, de Souza C, Gedde-Dahl T, Sengeloev H, Schanz U, Komarnicki M, Arroyo C, Tholouli E, Gluckman E, Esquirol A, Yakoub-Agha I, Gürman G, Olavarria E, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1259-61.

Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis
Kröger N
J ONCOL PRACT. 2016;12(7):629-31.

Response: Antilymphocyte Globulin for Chronic Graft-versus-Host Disease
Kröger N, Solano C, Bonifazi F
NEW ENGL J MED. 2016;374(19):1894-5.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella A, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuketang F, Ruutu T, Bonifazi F
NEW ENGL J MED. 2016;374(1):43-53.

Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
Merz M, Jansen L, Castro F, Hillengass J, Salwender H, Weisel K, Scheid C, Luttmann S, Emrich K, Holleczek B, Katalinic A, Nennecke A, Straka C, Langer C, Engelhardt M, Einsele H, Kröger N, Beelen D, Dreger P, Brenner H, Goldschmidt H
EUR J CANCER. 2016;62:1-8.

Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT
Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen J, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlich P, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M
HAEMATOLOGICA. 2016;101(9):1120-7.

Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research
Potter V, Iacobelli S, van Biezen A, Maertens J, Bourhis J, Passweg J, Yakhoub-Agha I, Tabrizi R, Bay J, Chevallier P, Chalandon Y, Huynh A, Cahn J, Ljungman P, Craddock C, Lenhoff S, Russell N, Fegueux N, Socié G, Benedetto B, Meijer E, Mufti G, de Witte T, Robin M, Kröger N
BIOL BLOOD MARROW TR. 2016;22(9):1615-1620.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuketang F, Socié G, Kröger N
BIOL BLOOD MARROW TR. 2016;22(7):1206-11.

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party
Rubio M, Savani B, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, Craddock C, Kröger N, Hallek M, Jindra P, Mohty M, Nagler A
J HEMATOL ONCOL. 2016;9(1):65.

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, Michallet M, Stelljes M, Jindra P, Arnold R, Kröger N, Mohty M, Nagler A
J HEMATOL ONCOL. 2016;9(1):89.

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT
Savani B, Labopin M, Kröger N, Finke J, Ehninger G, Niederwieser D, Schwerdtfeger R, Bunjes D, Glass B, Socié G, Ljungman P, Craddock C, Baron F, Ciceri F, Gorin N, Esteve J, Schmid C, Giebel S, Mohty M, Nagler A
HAEMATOLOGICA. 2016;101(6):773-80.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N
LEUKEMIA. 2016;30(10):2047-2054.

Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation
Stahl T, Rothe C, Böhme M, Kohl A, Kröger N, Fehse B
INT J MOL SCI. 2016;17(9):E1515.

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation
Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward K, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte R, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S
J CLIN ONCOL. 2016;34(19):2212-20.

2015

Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma
Auner H, Garderet L, Kröger N
BRIT J HAEMATOL. 2015;171(4):453-62.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria
Ayuketang F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2015;94(10):1727-32.

How we manage JAK inhibition in allogeneic transplantation for myelofibrosis
Ballinger T, Savani B, Gupta V, Kröger N, Mohty M
EUR J HAEMATOL. 2015;94(2):115-119.

SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation
Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H
LEUKEMIA. 2015;29(1):253-5.

Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT
Basak G, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, Beguin Y, Lang P, Koenecke C, Sykora K, Te Boome L, van Biezen A, van der Werf S, Mohty M, de Witte T, Marsh J, Dreger P, Kröger N, Duarte R, Ruutu T
AM J TRANSPLANT. 2015;15(3):705-14.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia
Brissot E, Labopin M, Beckers M, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele G, Craddock C, Yakoub-Agha I, Gürman G, Russell N, Aljurf M, Potter M, Nagler A, Ottmann O, Cornelissen J, Esteve J, Mohty M
HAEMATOLOGICA. 2015;100(3):392-9.

Assessment of bone marrow inflammation in patients with myelofibrosis: an (18)F-fluorodeoxyglucose PET/CT study
Derlin T, Alchalby H, Bannas P, Veldhoen S, Apostolova I, Triviai I, Bengel F, Kröger N
EUR J NUCL MED MOL I. 2015;42(5):696-705.

Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation
Derlin T, Büsche G, Kröger N
NUCL MED REV. 2015;18(1):35-6.

18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis
Derlin T, Clauditz T, Kröger N
CLIN NUCL MED. 2015;40(6):521-2.

Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation
Derlin T, Laqmani A, Veldhoen S, Apostolova I, Ayuketang F, Adam G, Kröger N, Bannas P
EUR RADIOL. 2015;25(5):1229-1237.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen H, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre C, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E
BIOL BLOOD MARROW TR. 2015;21(12):2039-51.

Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
Gratwohl A, Sureda A, Baldomero H, Gratwohl M, Dreger P, Kröger N, Ljungman P, McGrath E, Mohty M, Nagler A, Rambaldi A, de Elvira C, Snowden J, Passweg J, Apperley J, Niederwieser D, Stijnen T, Brand R
EBIOMEDICINE. 2015;2(12):2101-9.

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
Heuser M, Meggendorfer M, Cruz M, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F
LEUKEMIA. 2015;29(9):1942-45.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial
Iacobelli S, de Wreede L, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella A, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G
BONE MARROW TRANSPL. 2015;50(4):505-510.

Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Kharfan-Dabaja M, Labopin M, Bazarbachi A, Socie G, Kroeger N, Blaise D, Veelken H, Bermudez A, Or R, Lioure B, Beelen D, Fegueux N, Hamladji R, Nagler A, Mohty M
LEUKEMIA RES. 2015;39(9):933-7.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors
Klyuchnikov E, Bacher U, Kröger N, Hari P, Ahn K, Carreras J, Bachanova V, Bashey A, Cohen J, D'Souza A, Freytes C, Gale R, Ganguly S, Hertzberg M, Holmberg L, Kharfan-Dabaja M, Klein A, Ku G, Laport G, Lazarus H, Miller A, Mussetti A, Olsson R, Slavin S, Usmani S, Vij R, Wood W, Maloney D, Sureda A, Smith S, Hamadani M
BIOL BLOOD MARROW TR. 2015;21(12):2091-2099.

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma
Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger N, Hari P, Ku G, Ayala E, Chen A, Chen Y, Cohen J, Freytes C, Gale R, Kamble R, Kharfan-Dabaja M, Lazarus H, Martino R, Mussetti A, Savani B, Schouten H, Usmani S, Wiernik P, Wirk B, Smith S, Sureda A, Hamadani M
BONE MARROW TRANSPL. 2015;51(1):58-66.

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation
Koenecke C, Göhring G, de Wreede L, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N
HAEMATOLOGICA. 2015;100(3):400-8.

Current Challenges in Stem Cell Transplantation in Myelofibrosis
Kröger N
CURR HEMATOL MALIG R. 2015;10(4):344-50.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
Kröger N, Deeg J, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi A, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat U, Passamonti F, Rondelli D, Barosi G
LEUKEMIA. 2015;29(11):2126-33.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis
Kröger N, Giorgino T, Scott B, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg H, Passamonti F
BLOOD. 2015;125(21):3347-3350.

Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma
Lajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Kröger N, Atanackovic D
BRIT J HAEMATOL. 2015;171(5):752-62.

Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy
Lellek H, Franke G, Ruckert C, Wolters M, Wolschke C, Christner M, Büttner H, Alawi M, Kröger N, Rohde H
INT J MED MICROBIOL. 2015;305(8):902-909.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuketang F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kroger N
ACTA HAEMATOL-BASEL. 2015;134(3):146-154.

Efficacy and outcome of allogeneic transplantation in IgD and non secretory myeloma. A report on behalf of the myeloma subcommittee of the Chronic Malignancies Working Party of the EBMT
Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg A, Cornelissen J, Hamladji R, Martelli M, Petersen E, Rovira M, Bandini G, Kröger N, de Witte T
BIOL BLOOD MARROW TR. 2015;21(6):1054-8.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms
Parampalli Yajnanarayana S, Stübig T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Triviai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D
BRIT J HAEMATOL. 2015;169(6):824-33.

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte R, Dufour C, Falkenburg J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M
BONE MARROW TRANSPL. 2015;50(4):476-482.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg A, Verdonck L, Niederwieser D, de Witte T, Kröger N, Olavarria E
BIOL BLOOD MARROW TR. 2015;21(7):1230-1236.

Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party
Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis J, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E, de Witte T, Rocha V, Kroger N, Kröger N
BIOL BLOOD MARROW TR. 2015;21(3):489-95.

Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
Sahebi F, Iacobelli S, Biezen A, Volin L, Dreger P, Michallet M, Ljungman P, de Witte T, Henseler A, Schaap N, López-Corral L, Poire X, Passweg J, Hamljadi R, Thomas S, Schonland S, Gahrton G, Morris C, Kröger N, Garderet L
BONE MARROW TRANSPL. 2015;50(6):802-807.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin N, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen J, Baron F, Unger R, Nagler A, Mohty M
J CLIN ONCOL. 2015;33(28):3144-51.

Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation
Stahl T, Böhme M, Kröger N, Fehse B
EXP HEMATOL. 2015;43(6):462-468.

Stammzelltransplantation bei Multipler Sklerose. Hamburger Erfahrungen und internationaler Forschungsstand
Stellmann J, Stürner K, Ufer F, Havemeister S, Pöttgen J, Ayuketang F, Kröger N, Friese M, Heesen C
NERVENARZT. 2015;86(8):989-96.

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015
Sureda A, Bader P, Cesaro S, Dreger P, Duarte R, Dufour C, Falkenburg J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh J, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A
BONE MARROW TRANSPL. 2015;50(8):1037-56.

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhäuser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kröger N
BRIT J HAEMATOL. 2015;171(2):239-246.

CD133 marks a stem cell population that drives human Primary Myelofibrosis
Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, Stocking C, Kröger N
HAEMATOLOGICA. 2015;100(6):768-79.

Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission
van der Torren C, van Hensbergen Y, Luther S, Aghai Z, Rychnavská Z, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger E, Goulmy E, Hambach L
PLOS ONE. 2015;10(3):e0119595.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen J, Andersen N, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V
BIOL BLOOD MARROW TR. 2015;21(8):1515-23.

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D
J TRANSL MED. 2015;13:197.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
Yousef S, Kovacsovics-Bankowski M, Salama M, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D
HUM VACC IMMUNOTHER. 2015;11(7):1606-11.

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D
BLOOD CANCER J. 2015;5:e285.

2014

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera
Alchalby H, Kröger N
CL LYMPH MYELOM LEUK. 2014;14 Suppl:S36-41.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn J, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N
BIOL BLOOD MARROW TR. 2014;20(2):279-81.

Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic D, Luetkens T, Kröger N
LEUKEMIA. 2014;28(5):993-1000.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
Auner H, Szydlo R, Hoek J, Goldschmidt H, Stoppa A, Morgan G, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N
BONE MARROW TRANSPL. 2014;50(2):209-215.

Selected CD34 Stem cells for Graft Engineering: 34 Case Reports in Hematopoietic Stem Cell Transplantation
Aversa F, Kroger N
2014;1:.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation
Ayuketang F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2014;93(5):855-61.

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian J, Kröger N, Mesa R, Mc Mullin M, Pardanani A, Passamonti F, Samuelsson J, Vannucchi A, Reiter A, Silver R, Verstovsek S, Tognoni G, Barbui T
LEUKEMIA. 2014.

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT
Chalandon Y, Passweg J, Guglielmi C, Iacobelli S, Apperley J, Schaap N, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E
HAEMATOLOGICA. 2014;99(9):1492-8.

Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation
Chemaly R, Ullmann A, Stoelben S, Richard M, Bornhäuser M, Groth C, Einsele H, Silverman M, Mullane K, Brown J, Nowak H, Kölling K, Stobernack H, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin R, Ehninger G
NEW ENGL J MED. 2014;370(19):1781-9.

IMWG consensus on risk stratification in multiple myeloma
Chng W, Dispenzieri A, Chim C, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J, Sonneveld P, Cavo M, Usmani S, Durie B, Avet-Loiseau H
LEUKEMIA. 2014;28(2):269-77.

Relapse assessment following allogeneic SCT in patients with MDS and AML
Christopeit M, Kröger N, Haferlach T, Bacher U
ANN HEMATOL. 2014;93(7):1097-110.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation
de Lima M, Porter D, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Schmid C
BIOL BLOOD MARROW TR. 2014;20(1):4-13.

Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy?
de Witte T, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D, Yakoubagha I, Kröger N
CL LYMPH MYELOM LEUK. 2014;14 Suppl:S42-5.

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study
de Wreede L, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden C, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher G, Herr W, Choquet S, Niederwieser D, Sutton L, Kröger N, de Witte T, Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council J
AM J HEMATOL. 2014;89(2):174-80.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms
Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuketang F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N
EUR J HAEMATOL. 2014;92(3):189-94.

Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis
Gupta V, Gotlib J, Radich J, Kröger N, Rondelli D, Verstovsek S, Deeg H
BIOL BLOOD MARROW TR. 2014;20(9):1274-81.

Low frequency of calreticulin mutations in MDS patients
Heuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol F
LEUKEMIA. 2014.

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation
Hussein A, Halkes C, Socié G, Tichelli A, von dem Borne P, Schaap M, Foa R, Ganser A, Dufour C, Bacigalupo A, Locasciulli A, Aljurf M, Peters C, Robin M, van Biezen A, Volin L, De Witte T, Marsh J, Passweg J, Kröger N
BIOL BLOOD MARROW TR. 2014;20(9):1448-50.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuketang F, Reckhaus M, Blaise D, Kröger N
BIOL BLOOD MARROW TR. 2014;20(3):382-6.

Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation
Kröger N, Stübig T, Atanackovic D
BIOL BLOOD MARROW TR. 2014;20(2):168-72.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis
Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuketang F, von Huenerbein N, Kvasnicka H, Thiele J, Kreipe H, Büsche G
BIOL BLOOD MARROW TR. 2014;20(6):812-5.

Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell Transplantation: results of different dosage levels in clinical practice
Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger N
CLIN TRANSPLANT. 2014;28(3):286-91.

Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis
Lehmberg K, Albert M, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I
HAEMATOLOGICA. 2014;99(1):180-4.

Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation
Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels B, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
CANCER IMMUNOL IMMUN. 2014;63(11):1151-62.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Lussana F, Rambaldi A, Finazzi M, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N
HAEMATOLOGICA. 2014;99(5):916-21.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak G, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan M, Koristek Z, Lanza F, Lemoli R, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten H, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte R
BONE MARROW TRANSPL. 2014;49(7):865-72.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide
Morris C, de Wreede L, Scholten M, Brand R, van Biezen A, Sureda A, Dickmeiss E, Trneny M, Apperley J, Chiusolo P, van Imhoff G, Lenhoff S, Martinelli G, Hentrich M, Pabst T, Onida F, Quinn M, Kröger N, de Witte T, Ruutu T
TRANSFUSION. 2014;54(10):2514-22.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome
Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V
BONE MARROW TRANSPL. 2014;49(5):628-33.

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuketang F
ANTICANCER RES. 2014;34(4):1779-84.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party
Onida F, Brand R, van Biezen A, Schaap M, von dem Borne P, Maertens J, Beelen D, Carreras E, Alessandrino E, Volin L, Kuball J, Figuera A, Sierra J, Finke J, Kröger N, de Witte T
HAEMATOLOGICA. 2014;99(10):1582-90.

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R, Chaturvedi A, Stadler M, Eder M, Göhring G, Koenigsmann M, Kloos A, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kreipe H, Ganser A, Kröger N, Heuser M
LEUKEMIA. 2014;28(7):1552-5.

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation
Passweg J, Baldomero H, Peters C, Gaspar H, Cesaro S, Dreger P, Duarte R, Falkenburg J, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal A
BONE MARROW TRANSPL. 2014;49(6):744-50.

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients
Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Kröger N, Atanackovic D
BLOOD CANCER J. 2014;4:e212.

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis
Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn J, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay J, Chalandon Y, Kröger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A
BIOL BLOOD MARROW TR. 2014;20(11):1841-6.

Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D
BONE MARROW TRANSPL. 2014;49(2):168-73.

Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT
Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, Dinkel A, Kunze S, Balck F, Kröger N, Koch U, Mehnert A
BONE MARROW TRANSPL. 2014;49(9):1217-22.

Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel N, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen D, Haas R, Kobbe G
BIOL BLOOD MARROW TR. 2014.

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis
Stern M, de Wreede L, Brand R, van Biezen A, Dreger P, Mohty M, de Witte T, Kröger N, Ruutu T
LEUKEMIA. 2014;28(11):2235-40.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuketang F, Kröger N
LEUKEMIA. 2014;28(8):1736-8.

5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity
Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder T, Fehse B, Kröger N
MEDIAT INFLAMM. 2014;2014:418292.

Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M
HAEMATOLOGICA. 2014.

Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
Triviai I, Ziegler M, Bergholz U, Oler A, Stübig T, Prassolov V, Fehse B, Kozak C, Kröger N, Stocking C
P NATL ACAD SCI USA. 2014;111(23):8595 - 8600.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
Wolschke C, Zabelina T, Ayuketang F, Alchalby H, Berger J, Klyuchnikov E, Pein U, Schumacher S, Amtsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N
BONE MARROW TRANSPL. 2014;49(1):126-30.

2013

Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders
Atanackovic D, Nowottne U, Freier E, Weber C, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl M, Bokemeyer C, Deter H
STRESS. 2013;16(4):421-8.

The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting
Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki J, Bokemeyer C
HUM VACC IMMUNOTHER. 2013;9(12):2533-42.

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous Transplantation: a study by the European Group for Blood and Marrow Transplantation
Auner H, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N
BONE MARROW TRANSPL. 2013;48(11):1395-400.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies
Avigan D, Hari P, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Hsu K
BIOL BLOOD MARROW TR. 2013;19(12):1661-9.

Donor choice according to age for allo-SCT for AML in complete remission
Ayuketang F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2013;48(8):1028-32.

Moderne Bildgebungsverfahren beim Multiplen Myelom
Bannas P, Kröger N, Adam G, Derlin T
ROFO-FORTSCHR RONTG. 2013;185(1):26-33.

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy
Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B
HUM VACC IMMUNOTHER. 2013;9(6):1205-16.

Cytogenetics of extramedullary manifestations in multiple myeloma
Billecke L, Murga Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann H, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G
BRIT J HAEMATOL. 2013;161(1):87-94.

Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic Syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data
Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhäuser M, Kobbe G, Germing U, de Witte T, Kröger N
PLOS ONE. 2013;8(10):e74368.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change
Christopeit M, Kuss O, Finke J, Bacher U, Beelen D, Bornhäuser M, Schwerdtfeger R, Bethge W, Basara N, Gramatzki M, Tischer J, Kolb H, Uharek L, Meyer R, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C
J CLIN ONCOL. 2013;31(26):3259-71.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T, Habermann C, Adam G, Kröger N, Weber C
EUR RADIOL. 2013;23(2):570-8.

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study
Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella A, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N
BLOOD. 2013;121(25):5055-63.

Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation
Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganser A, Ghavamzadeh A, Koh M, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socié G, Tischer J, Oneto R, Passweg J, Marsh J
HAEMATOLOGICA. 2013;98(11):1804-9.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation
Gress R, Miller J, Battiwalla M, Bishop M, Giralt S, Hardy N, Kröger N, Wayne A, Landau D, Wu C
BIOL BLOOD MARROW TR. 2013;19(11):1537-45.

Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Koch M, Graeser C, Lehnhardt A, Pollok J, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B
TRANSPL INT. 2013;26(8):64-68.

Aktuelle Therapieoptionen bei der Myelofibrose
Kröger N
2013. Aktuelle Therapieoptionen bei der Myelofibrose. Döhner K, Griesshammer M (Hrsg.). 2. Aufl. Uni-Med, 56-63.

From nuclear to a global Family: more donors for MDS
Kröger N
BLOOD. 2013;122(11):1848-50.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings.
Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T
LEUKEMIA. 2013;27(3):604-609.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K, Burchert A, Stübig T, Wolschke C, Ayuketang F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander A
BONE MARROW TRANSPL. 2013;48(3):403-407.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.
Martino R, de Wreede L, Fiocco M, van Biezen A, von Dem Borne P, Hamladji R, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M
BONE MARROW TRANSPL. 2013;48(6):761-770.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Hematopoietic SCT in Europe: data and trends in 2011
Passweg J, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte R, Falkenburg J, Kröger N, Farge-Bancel D, Gaspar H, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A
BONE MARROW TRANSPL. 2013;48(9):1161-7.

Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation.
Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Arturo I, Arcese W, Beelen D, Cornelissen J, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P
BLOOD. 2013;121(3):440-446.

CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell Transplantation: a report from the Acute Leukemia Working Party of EBMT
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganser A, Niederwieser D, Polge E, Blau I, Mohty M
BLOOD. 2013;122(19):3359-64.

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G
LEUKEMIA. 2013;27(6):1229-35.

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation
Schroeder T, Fröbel J, Cadeddu R, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G
LEUKEMIA. 2013;27(9):1910-3.

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi A, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G
BLOOD. 2013;122(8):1395-8.

SETBP1 mutation analysis in 944 patients with MDS and AML
Thol F, Suchanek K, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann W, Krauter J, Kröger N, Ganser A, Heuser M
LEUKEMIA. 2013;27(10):2072-5.

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
van Gelder M, de Wreede L, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kröger N
LEUKEMIA. 2013;27(4):879-888.

Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12
Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeyer D, Schwoebel F, Purschke W, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F
CLIN PHARMACOL THER. 2013;94(1):150-7.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction
Wayne A, Giralt S, Kröger N, Bishop M
BIOL BLOOD MARROW TR. 2013;19(11):1534-6.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N
EXP HEMATOL. 2013;41(2):133-134.

2012

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H, Yunus D, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka H, Büsche G, Ayuketang Ayuk F, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;157(1):75-85.

Role of interleukin 16 in multiple myeloma.
Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander A, Marx A, Uhlig R, Zustin J, Bokemeyer C, Kröger N
JNCI-J NATL CANCER I. 2012;104(13):1005-1020.

Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.
Bannas P, Hentschel H, Bley T, Treszl A, Zu Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber C
EUR RADIOL. 2012;22(9):2007-2012.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.
Billecke L, Murga-Penas E, May A, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G
ANTICANCER RES. 2012;32(5):2031-2034.

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl M, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel W, Ehninger G, Beelen D, Schetelig J, Stelljes M
LANCET ONCOL. 2012;13(10):1035-1044.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge W, Ottinger H, Stelljes M, Zander A, Volin L, Heim D, Schwerdtfeger R, Kolbe K, Mayer J, Maertens J, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G, , Kröger N
BIOL BLOOD MARROW TR. 2012;18(11):1716-1726.

Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.
Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübig T, Sierich H, Badbaran A, Eiermann T, Binder T, Kröger N
Clin Dev Immunol. 2012;2012:652130.

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Hübel K, Fresen M, Apperley J, Basak G, Douglas K, Gabriel I, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte R
BONE MARROW TRANSPL. 2012;47(8):1046-1050.

Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.
Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;159(2):172-181.

Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
Kobold S, Luetkens T, Bartels B, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2012;2012:134081.

Allogene Blutstammzelltransplantation
Kröger N
2012. Multiples Myelom: Moderne Diagnoseverfahren, aktuelle Behandlungsoptionen und Supportivtherapie. Deutscher Ärzte-Verlag: 105-116.

Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome.
Kröger N
BLOOD. 2012;119(24):5632-5639.

Allogene Stammzelltransplantation zur Therapie der Osteomyelofibrose
Kröger N
2012. Blutstammzelltransplantation - Bilanz des aktuellen Wissens. düsseldorf university press: 139-155.

Allogene Stammzelltransplantation bei Myelofibrose
Kröger N, Alchalby H
2012. Aktuelle Therapieoptionen bei der Myelofibrose. UNI-MED Verlag: 47-56.

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis.
Kröger N, Kvasnicka M, Thiele J
Fibrogenesis Tissue Repair. 2012;5 Suppl 1:25.

Immunotherapy for multiple myeloma.
Kröger N, Mohty M, Nagler A, Yi Q
Clin Dev Immunol. 2012;2012:797165.

Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience.
Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois C, Tournilhac O, Buzyn A, Rio B, Moles M, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau J, Moreau P, Leux C, Mohty M
ANN ONCOL. 2012;23(10):2695-2703.

Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F, Kröger N, Gabriel I, Hübel K, Apperley J, Basak G, Douglas K, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte R
BIOL BLOOD MARROW TR. 2012;18(2):314-317.

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation.
Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M, Blood A, Transplantation M
BLOOD. 2012;119(6):1599-1606.

Therapy-related myeloid neoplasms following treatment with radioiodine.
Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere A, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U
HAEMATOLOGICA. 2012;97(2):206-212.

2011

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuketang Ayuk F, Zander A, Kröger N
BONE MARROW TRANSPL. 2011;47(1):143-145.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N
AM J HEMATOL. 2011;86(11):918-922.

Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander A, Marx A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2011;96(10):1512-1520.

Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Bacher U, Haferlach T, Fehse B, Schnittger S, Kröger N
SCI WORLD J. 2011;11:310-319.

Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
Bacher U, Haferlach T, Schnittger S, Kreipe H, Kröger N
BRIT J HAEMATOL. 2011;153(2):149-167.

Unusual course of myelodysplastic syndrome with presumed familial origin.
Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander A, Bokemeyer C, Haferlach T, Kröger N
ACTA HAEMATOL-BASEL. 2011;126(4):234-237.

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Hehlmann R, Hoffman R, Kiladjian J, Kröger N, Mesa R, McMullin M, Pardanani A, Passamonti F, Vannucchi A, Reiter A, Silver R, Verstovsek S, Tefferi A, LeukemiaNet E
J CLIN ONCOL. 2011;29(6):761-770.

National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
Bishop M, Alyea E, Cairo M, Falkenburg J, June C, Kröger N, Little R, Miller J, Pavletic S, Porter D, Riddell S, van Besien K, Wayne A, Weisdorf D, Wu R, Giralt S
BIOL BLOOD MARROW TR. 2011;17(4):443-454.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Cavo M, Rajkumar S, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos M, Attal M, Sonneveld P, Boccadoro M, Anderson K, Richardson P, Bensinger W, Johnsen H, Kröger N, Gahrton G, Bergsagel P, Vesole D, Einsele H, Jagannath S, Niesvizky R, Durie B, Jesus S, Lonial S, Group I
BLOOD. 2011;117(23):6063-6073.

Assessment of physiologic natural killer cell cytotoxicity in vitro.
Duske H, Sputtek A, Binder T, Kröger N, Schrepfer S, Eiermann T
HUM IMMUNOL. 2011;72(11):1007-1012.

Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K, Fresen M, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander A, Albert M, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N
BONE MARROW TRANSPL. 2011;46(8):1045-1052.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuketang Ayuk F, Zander A
ANN HEMATOL. 2011;2011:974658.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels B, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D
Clin Dev Immunol. 2011;2011:302145.

Approaches to relapse after allogeneic stem cell transplantation.
Kröger N
CURR OPIN ONCOL. 2011;23(2):203-208.

Minimal residual disease following allogeneic hematopoietic stem cell transplantation.
Kröger N, Miyamura K, Bishop M
BIOL BLOOD MARROW TR. 2011;17(1):94-100.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hildebrandt Y, Atanackovic D, Alchalby H, Ayuketang Ayuk F, Zander A, Bacher U, Eiermann T
LEUKEMIA. 2011;25(10):1657-1661.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.
Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim Z, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T
HAEMATOLOGICA. 2011;96(2):291-297.

Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.
Langebrake C, Bernhardt F, Baehr M, Kröger N, Zander A
INT J CLIN PHARM-NET. 2011;33(6):918-924.

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H, Waldenmaier D, Dahlke J, Ayuketang Ayuk F, Wolschke C, Kröger N, Zander A
MYCOSES. 2011;54(1):39-44.

Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
Muth M, Engelhardt B, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe H, Bock O
ANN HEMATOL. 2011;90(1):33-40.

Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.
Oyekunle A, Haferlach T, Kröger N, Klyuchnikov E, Zander A, Schnittger S, Bacher U
Adv Hematol. 2011;2011:154745.

Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander A, Baccarani M, Bacher U
ACTA HAEMATOL-BASEL. 2011;126(1):30-39.

First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia.
Peinemann F, Grouven U, Kröger N, Bartel C, Pittler M, Lange S
PLOS ONE. 2011;6(4):18572.

High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review.
Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R, Kulig M
PLOS ONE. 2011;6(2):17127.

Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT.
Robin M, Sanz G, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kröger N, Rocha V
LEUKEMIA. 2011;25(1):75-81.

Bioequivalence comparison of a new freezing bag (CryoMACS(®)) with the Cryocyte(®) freezing bag for cryogenic storage of human hematopoietic progenitor cells.
Sputtek A, Lioznov M, Kröger N, Rowe A
CYTOTHERAPY. 2011;13(4):481-489.

2010

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2010;45(9):1404-1407.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Christian T, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander A, Kröger N
BLOOD. 2010;116(18):3572-3581.

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.
Alchalby H, Kröger N
CURR HEMATOL MALIG R. 2010;5(2):53-61.

Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes.
Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander A, Haferlach T
BIOL BLOOD MARROW TR. 2010;16(1):1-11.

Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen D, Kern W, Schnittger S, Haferlach C
BIOL BLOOD MARROW TR. 2010;16(12):1649-1657.

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Bishop M, Alyea E, Cairo M, Falkenburg J, June C, Kröger N, Little R, Miller J, Pavletic S, Porter D, Riddell S, van Besien K, Wayne A, Weisdorf D, Wu R, Giralt S
BIOL BLOOD MARROW TR. 2010;16(5):563-564.

An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body.
Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff A, Kröger N, Bokemeyer C, Atanackovic D
J IMMUNOL METHODS. 2010;358(1-2):56-65.

The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander A, Bokemeyer C, Kröger N, Atanackovic D
EXP HEMATOL. 2010;38(10):860-867.

Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.
Carreras E, Cahn J, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant J
ANTICANCER RES. 2010;30(7):2977-2984.

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.
Casper J, Wolff D, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kröger N, Hilgendorf I, Baumgart J, Mylius H, Pichlmeier U, Freund M
J CLIN ONCOL. 2010;28(20):3344-3351.

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny.
Cavattoni I, Ayuketang Ayuk F, Zander A, Zabelina T, Bacher A, Cayiroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1530-1535.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.
Cavattoni I, Zabelina T, Ayuketang Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2010;51(1):146-148.

Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency.
Hambach L, Aghai Z, Pool J, Kröger N, Goulmy E
J IMMUNOL. 2010;185(8):4582-4589.

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuketang Ayuk F, Wiedemann B, Lioznov M, Freiberger P, Zalyalov Y, Zander A, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1450-1463.

Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT.
Koenecke C, Hertenstein B, Schetelig J, van Biezen A, Dammann E, Gratwohl A, Ganser A, Schleuning M, Bornhäuser M, Jacobsen N, Kröger N, Niederwieser D, de Witte T, Ruutu T
AM J TRANSPLANT. 2010;10(8):1897-1906.

Unrelated stem cell transplantation for patients with multiple myeloma.
Kröger N
CURR OPIN HEMATOL. 2010;17(6):538-543.

Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients.
Kröger N, Asenova S, Gerritzen A, Bacher U, Zander A
BLOOD. 2010;115(16):3413-3415.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz M, Dreger P, Khouri I, Macapinlac H, Macapintac H, Olavarria E, Radich J, Stock W, Vose J, Weisdorf D, Willasch A, Giralt S, Bishop M, Wayne A
BIOL BLOOD MARROW TR. 2010;16(9):1187-1211.

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
Kröger N, Bacher U, Bader P, Böttcher S, Borowitz M, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose J, Weisdorf D, Willasch A, Giralt S, Bishop M, Wayne A
BIOL BLOOD MARROW TR. 2010;16(10):1325-1346.

Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
Kröger N, Einsele H, Derigs G, Wandt H, Krüll A, Zander A
BIOL BLOOD MARROW TR. 2010;16(6):861-864.

Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.
Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, Zander A, Heinzelmann M, Brand R, Gahrton G, Morris C, Niederwieser D, de Witte T
BRIT J HAEMATOL. 2010;148(2):323-331.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle R, Durie B, Rajkumar S, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole D, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen W, Anderson K, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson P, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, Group I
LEUKEMIA. 2010;24(6):1121-1127.

Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet J, Niederwieser D, Kröger N, Mufti G, Witte D, Theo M
J CLIN ONCOL. 2010;28(3):405-411.

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
Lokhorst H, Einsele H, Vesole D, Bruno B, Jesus S, Pérez-Simon J, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W
J CLIN ONCOL. 2010;28(29):4521-4530.

Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels B, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf T, Atanackovic D
LEUKEMIA RES. 2010;34(12):1647-1655.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.
Neth O, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuketang F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston R, Klein N, Zander A
BONE MARROW TRANSPL. 2010;45(1):13-9.

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia.
Ocheni S, Oyekunle A, Kröger N, Ayuketang Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjalle R, Wolschke C, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2010;125(3):175-178.

Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.
Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A
EXP MOL PATHOL. 2010;89(2):175-181.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J, Hardy N, Kröger N, Leis J, Levine J, Maloney D, Peggs K, Rowe J, Wayne A, Giralt S, Bishop M, van Besien K
BIOL BLOOD MARROW TR. 2010;16(11):1467-1503.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A, Hardan I, Ayuketang Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander A, Kröger N, Nagler A
CANCER-AM CANCER SOC. 2010;116(15):3621-3630.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

2009

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.
Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander A, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2009;*95*(5):785-793.

Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.
Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander A, Bokemeyer C, Kröger N
CLIN CANCER RES. 2009;15(4):1343-1352.

Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies.
Ayuketang Ayuk F, Maywald N, Hannemann S, Larsen U, Zander A, Kröger N
ANTICANCER RES. 2009;29(4):1355-1360.

Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma.
Ayuketang Ayuk F, Zander A, Kröger N
ANN HEMATOL. 2009;88(5):401-404.

Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Bacher U, Asenova S, Badbaran A, Zander A, Alchalby H, Fehse B, Kröger N, Lange C, Ayuketang Ayuk F
CLIN EXP MED. 2009.

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A, Kröger N
EXP HEMATOL. 2009;37(1):135-142.

Interactive diagnostics in the indication to allogeneic SCT in AML.
Bacher U, Haferlach C, Schnittger S, Kern W, Kröger N, Zander A, Haferlach T
BONE MARROW TRANSPL. 2009;43(10):745-756.

Safety of conditioning agents for allogeneic haematopoietic transplantation.
Bacher U, Klyuchnikov E, Wiedemann B, Kröger N, Zander A
EXPERT OPIN DRUG SAF. 2009;8(3):305-315.

The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004.
Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen D, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttorp M, Kolb H, Kröger N, Zander A
ANN HEMATOL. 2009.

Outcome of transplantation for myelofibrosis.
Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B, Cervantes F, Devine S, Gale R, Gupta V, Hahn T, Hogan W, Kröger N, Litzow M, Marks D, Maziarz R, McCarthy P, Schiller G, Harry C, Roy V, Wiernik P, Horowitz M, Giralt S, Arora M
BIOL BLOOD MARROW TR. 2009;*16*(3):358-367.

Identification of new target molecules PTK2, TGFBR2 and CD9 overexpressed during advanced bone marrow remodelling in primary myelofibrosis.
Bock O, Muth M, Theophile K, Winter M, Hussein K, Büsche G, Kröger N, Kreipe H
BRIT J HAEMATOL. 2009.

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G
BONE MARROW TRANSPL. 2009;*45*(5):872-876.

Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival.
de Witte T, Brand R, van Biezen A, Mufti G, Ruutu T, Finke J, von Dem Borne P, Vitek A, Delforge M, Alessandrino P, Harlahakis N, Russell N, Martino R, Verdonck L, Kröger N, Niederwieser D
BRIT J HAEMATOL. 2009.

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V, Kröger N, Aschan J, Xu W, Leber B, Dalley C, Sabloff M, Lipton J, Messner H, Brune M
BONE MARROW TRANSPL. 2009.

Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuketang Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(4):185-192.

Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation.
Hussein K, Bock O, Theophile K, Schlue J, Ballmaier M, Kröger N, Göhring G, Büsche G, Kreipe H
BLOOD. 2009;113(6):1391-1392.

Sensitising leukemic cells by targeting microenvironment.
Klyuchnikov E, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(3):319-320.

Current status and perspectives of tyrosine kinase inhibitor treatment in the post-transplant period in patients with chronic myeloid leukemia (CML).
Klyuchnikov E, Kröger N, Brümmendorf T, Wiedemann B, Zander A, Bacher U
BIOL BLOOD MARROW TR. 2009.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E, Schafhausen P, Kröger N, Brümmendorf T, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuketang Ayuk F, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(1):6-10.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuketang Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A
BLOOD. 2009;113(8):1866-1868.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N, Badbaran A, Lioznov M, Schwartz S, Zeschke S, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A
EXP HEMATOL. 2009;37(7):791-798.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T
HAEMATOLOGICA. 2009;94(4):542-549.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf G, Einsele H, Zabelina T, Kvasnicka H, Thiele J, Brand R, Zander A, Niederwieser D, Witte d, Theo M
BLOOD. 2009;114(26):5264-5270.

HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N, Zabelina T, Binder T, Ayuketang Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A
BIOL BLOOD MARROW TR. 2009;15(4):454-462.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuketang Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander A, Blaise D, Mohty M, Kröger N
BONE MARROW TRANSPL. 2009.

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Lippert E, Girodon F, Hammond E, Jelinek J, Reading N, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal J, Skoda R, Hermouet S
HAEMATOLOGICA. 2009;94(1):38-45.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski G, Schafhausen P, Zander A, Ayuketang Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf T, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2009;50(4):551-558.

Outcome of allo-SCT for chronic myelomonocytic leukemia.
Ocheni S, Kröger N, Zabelina T, Zander A, Bacher U
BONE MARROW TRANSPL. 2009;43(8):659-661.

Syngenic graft-versus-chronic-myeloid-leukemia-effect?
Ocheni S, Schafhausen P, Bacher U, Fehse B, Kröger N
CTT-Cell Ther Transpl. 2009;1(3):66-68.

Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.
Ocheni S, Zabelina T, Bacher U, Ayuketang Ayuk F, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(4):612-618.

Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.
Peinemann F, Grouven U, Kröger N, Pittler M, Zschorlich B, Lange S
HAEMATOLOGICA. 2009;94(12):1732-1742.

Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation.
Perz J, Hegenbart U, Kröger N, Otto G, Ho A, Dreger P
HAEMATOLOGICA. 2009;94(4):594-596.

Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect".
Schonland S, Kröger N, Wolschke C, Dreger P, Ho A, Hegenbart U
HAEMATOLOGICA. 2009;94(3):439-441.

Severe aplastic anaemia following leflunomide therapy.
Wüsthof M, Smirnova A, Bacher U, Kröger N, Zander A, Schuch G, Bokemeyer C
RHEUMATOLOGY. 2009.

2008

CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander A, Fehse B, Bokemeyer C, Kröger N
HAEMATOLOGICA. 2008;93(3):423-430.

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia.
Ayuketang Ayuk F, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander A, Kröger N
LEUKEMIA RES. 2008;32(8):1200-1206.

Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander A
EXP HEMATOL. 2008;36(8):1047-1054.

Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander A
BIOL BLOOD MARROW TR. 2008;14(8):913-919.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuketang Ayuk F, Perez-Simon J, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer H, Alegre A, Lahuerta J, Atanackovic D, Wolschke C, Nagler A, Zander A, Miguel S, Kröger N, Kröger N
HAEMATOLOGICA. 2008;93(9):1343-1350.

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.
Bacher U, Zander A, Haferlach T, Schnittger S, Fehse B, Kröger N
BONE MARROW TRANSPL. 2008;42(3):145-157.

Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
Benjamini O, Koren-Michowitz M, Amariglio N, Kröger N, Nagler A, Shimoni A
LEUKEMIA. 2008;22(10):1961-1963.

Safety of percutaneous dilational tracheostomy in hematopoietic stem cell transplantation recipients requiring long-term mechanical ventilation.
Kluge S, Baumann H, Nierhaus A, Kröger N, Meyer A, Kreymann K
J CRIT CARE. 2008;23(3):394-398.

Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS.
Kröger N
HEMATOL-AM SOC HEMAT. 2008;60-67.

Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N, Mesa R
LEUKEMIA. 2008;22(3):474-486.

Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M, Badbaran A, Fehse B, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2008;41(10):913-916.

Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM.
Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander A
BONE MARROW TRANSPL. 2008;42(2):121-128.

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kröger N, Zabelina T, Sobottka I, Ayuketang Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander A, Bacher U
BONE MARROW TRANSPL. 2008;42(3):181-186.

Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.
Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D
BRIT J CANCER. 2008;99(6):930-938.

Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott B, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorror M, Ehninger G, Deeg H
BIOL BLOOD MARROW TR. 2008;14(11):1217-1225.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón J, Simon-Perez J, Gutierrez N, Fiedler W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Murga-Penas E, Dierlamm J, Ayuketang Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Miguel J, Nagler A, Kröger N
LEUKEMIA. 2008;22(6):1250-1255.

Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF.
Siebolts U, Thiele J, Zander T, Ditschkowski M, Beelen D, Kröger N, Fehse B, Wickenhauser C
ONCOL REP. 2008;19(1):287-292.

Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Zander A, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel W, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W
ANN ONCOL. 2008;19(6):1082-1089.

2007

Autologous stem cell transplantation in myelodysplastic syndromes.
de Witte T, Suciu S, Brand R, Muus P, Kröger N
SEMIN HEMATOL. 2007;44(4):274-277.

Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland S, Verdonck L, Volin L, de Witte T, Niederwieser D
HAEMATOLOGICA. 2007;92(11):1513-1518.

Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation.
Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander A, Ehninger G, Kröger N
ANTICANCER RES. 2007;27(6):4377-4380.

Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
Kröger N
LEUKEMIA. 2007;21(9):1851-1858.

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, Reiter A, Zabelina T, Zander A, Fehse B
BLOOD. 2007;109(3):1316-1321.

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka H
EXP HEMATOL. 2007;35(11):1719-1722.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf H, Einsele H, Volpert S, Heinecke A, Berdel W, Kienast J
BRIT J HAEMATOL. 2007;138(3):330-337.

Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
Mösbauer U, Ayuketang Ayuk F, Schieder H, Lioznov M, Zander A, Kröger N
HAEMATOLOGICA. 2007;92(2):275-276.

Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation.
Thiele J, Varus E, Siebolts U, Kvasnicka H, Wickenhauser C, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger N
HISTOL HISTOPATHOL. 2007;22(4):365-372.

2006

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer H, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl M, Wandt H, Theuser C, Ehninger G, Zander A
EUR J HAEMATOL. 2006;76(1):9-17.

Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
Dahlke J, Kröger N, Zabelina T, Ayuketang Ayuk F, Wolschke C, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(2):155-163.

The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
de Witte T, Brand R, van Biezen A, Delforge M, Biersack H, Or R, Meloni G, Bandini B, Sierra J, Kröger N, Gratwohl A, Niederwieser D
HAEMATOLOGICA. 2006;91(6):750-756.

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Donk v, Kröger N, Kröger N, Hegenbart U, Corradini P, Miguel S, Jesus F, Goldschmidt H, Perez-Simon J, Zijlmans M, Ayuketang Ayuk F, Montefusco V, Ayuk F, Oers v, Marinus H, Nagler A, Verdonck L, Lokhorst H
BLOOD. 2006;107(8):3415-3416.

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.
Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F
BLOOD. 2006;107(7):3002-3008.

Comparison of flow cytometry vs. a haematology cell analyser-based method to guide the optimal time-point for peripheral blood stem cell apheresis.
Gutensohn K, Magens M, Krüger W, Kröger N, Kühnl P
VOX SANG. 2006;90(1):53-58.

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuketang Ayuk F, Dahlke J, Eiermann T, Zander A
TRANSPLANTATION. 2006;82(8):1024-1030.

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N, Brand R, van Biezen A, Cahn J, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T
BONE MARROW TRANSPL. 2006;37(2):183-189.

Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann H, Meier C, Lohrmann H, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf H, Kolbe K, Burock K, Zander A, Nitz U
J CLIN ONCOL. 2006;24(24):3919-3926.

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander A, Löning T
CLIN CANCER RES. 2006;12(1):159-168.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuketang Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A
BONE MARROW TRANSPL. 2006;37(4):339-344.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N, Zabelina T, Ayuketang Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A
EXP HEMATOL. 2006;34(6):770-775.

Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuketang Ayuk F, Zander A, Fehse B
EXP HEMATOL. 2006;34(5):688-694.

Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti G, Kröger N, Zander A, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, López-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter A, Marr K, Dornbusch H, Einsele H
BLOOD. 2006;108(9):2928-2936.

CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
Oyekunle A, Koehl U, Schieder H, Ayuketang Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N
CYTOTHERAPY. 2006;8(4):375-380.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle A, Kröger N, Zabelina T, Ayuketang Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(1):45-50.

Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation.
Schönland S, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kröger N, Giorgio L, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G
BLOOD. 2006;107(6):2578-2584.

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk N, Kröger N, Hegenbart U, Corradini P, San Miguel J, Goldschmidt H, Perez-Simon J, Zijlmans M, Raymakers R, Montefusco V, Ayuketang Ayuk F, van Oers M, Nagler A, Verdonck L, Lokhorst H
BONE MARROW TRANSPL. 2006;37(12):1135-1141.

2005

Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells
Fang L, Fehse B, Engel M, Zander A, Kröger N
TRANSPLANTATION. 2005;79(3):369-371.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.
Shimoni A, Kröger N, Zabelina T, Ayuketang Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander A, Nagler A
LEUKEMIA. 2005;19(1):7-12.

Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation.
Thiele J, Kvasnicka H, Dietrich H, Stein G, Hann M, Kaminski A, Rathjen N, Metz K, Beelen D, Ditschkowski M, Zander A, Kröger N
HISTOL HISTOPATHOL. 2005;20(3):879-889.

2004

Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
Kiehl M, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kröger N, Stelljes M, Bornhaeuser M, Martin H, Scheid C, Ganser A, Zander A, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser A, Ringden O
J CLIN ONCOL. 2004;22(14):2816-2825.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon J, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas J, Schwerdtfeger R, Kiehl M, Fauser A, Sayer H, Leon A, Beyer J, Zabelina T, Ayuketang Ayuk F, Miguel S, Jesus F, Brand R, Zander A
BIOL BLOOD MARROW TR. 2004;10(10):698-708.

Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation.
Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon J, Miguel S, Jesus F, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer H, Myint H, Zabelina T, Zabelina T, Dierlamm J, Hinke A, Zander A
BLOOD. 2004;103(11):4056-4061.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander A
BLOOD. 2004;104(10):3361-3363.

2003

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation.
Fehse N, Fehse B, Kröger N, Zabelina T, Freiberger P, Krüger W, Kabisch H, Erttmann R, Zander A
J HEMATOTH STEM CELL. 2003;12(2):237-242.

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuketang Ayuk F, Krüll A, Zander A
BONE MARROW TRANSPL. 2003;31(11):973-979.

2002

Binding of activated platelets to WBCs in vivo after transfusion.
Gutensohn K, Geidel K, Brockmann M, Siemensen M, Krueger W, Kröger N, Kuehnl P
TRANSFUSION. 2002;42(10):1373-1380.

Platelet function testing in apheresis products: flow cytometric, resonance thrombographic (RTG) and rotational thrombelastographic (roTEG) analyses.
Gutensohn K, Geidel K, Kröger N, Eifrig B, Crespeigne N, Kuehnl P
TRANSFUS APHER SCI. 2002;26(3):147-155.

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuketang Ayuk F, Renges H, Panse J, Erttmann R, Zander A
BRIT J HAEMATOL. 2002;119(3):769-772.

Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer.
Hoeller U, Juergen H, Kröger N, Krueger W, Jaenicke F, Alberti W
INT J RADIAT ONCOL. 2002;53(5):1234-1239.

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma.
Kröger N, Schwerdtfeger R, Kiehl M, Sayer H, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, Zander A
BLOOD. 2002;100(3):755-760.

Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease.
Schetelig J, Kröger N, Held T, Christian T, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander A, Siegert W
HAEMATOLOGICA. 2002;87(3):299-305.

Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR
Tögel F, Kröger N, Korioth F, Fehse B, Zander A
J HEMATOTH STEM CELL. 2002;11(6):971-976.

2000

Extracorporeal plateletpheresis induces the interaction of activated platelets with white blood cells.
Gutensohn K, Alisch A, Krueger W, Kröger N, Kuehnl P
VOX SANG. 2000;78(2):101-105.

1999

Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients.
Dürken M, Horstmann M, Bieling P, Erttmann R, Kabisch H, Löliger C, Schneider E, Hellwege H, Krüger W, Kröger N, Zander A, Janka G
BRIT J HAEMATOL. 1999;106(4):1052-1058.

Semi-automated flow cytometric analysis of CD34-expressing hematopoietic cells in peripheral blood progenitor cell apheresis products.
Gutensohn K, Carrero I, Krueger W, Kröger N, Schäfer P, Luedemann K, Kuehnl P
TRANSFUSION. 1999;39(11-12):1220-1226.

1998

Purging and haemopoietic progenitor cell selection by CD34+ cell separation
Krüger W, Gruber M, Hennings S, Fehse N, Fehse B, Gutensohn K, Kröger N, Zander A
BONE MARROW TRANSPL. 1998;21(7):665-671.

Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Lehnert M, Mross K, Schueller J, Thuerlimann B, Kröger N, Kupper H
BRIT J CANCER. 1998;77(7):1155-1163.

1991

Metolazone in der Behandlung fortgeschrittener therapieresistenter dilatativer Kardiomyopathie
Kröger N, Szuba J, Frenzel H
MED KLIN-INTENSIVMED. 1991;86(6):305-8, 332.

1990

Metolazone for severe dilated cardiomyopathy refractory to conventional therapy
Kröger N, Szuba J, Buhl C, Pompecki R, Frenzel H
LANCET. 1990;335(8696):1031-2.

Letzte Aktualisierung aus dem FIS: 02.12.2024 - 23:35 Uhr